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ABSTRACT 
Ricardo J. Antonia: IKK family kinases regulate cell growth, metabolism and autophagy by 
phosphorylation of key substrates  
(Under the direction of Albert S. Baldwin) 
 
Inflammation is now widely accepted to be an essential mediator of the balance between cell 
growth, metabolism, and autophagy. A group of kinases belonging to the IκB kinase (IKK) 
family has emerged as critical regulators of the interplay between inflammation and energy 
usage in both healthy and diseased tissues. They accomplish this task by phosphorylation of a 
variety of protein targets. My dissertation work has focused on two of these phosphorylation 
targets. In Chapter 2, I characterized the role of IKK in regulating the AMP-activated protein 
kinase (AMPK), the primary sensor of ATP levels in a cell. I found that IKK directly 
phosphorylates Thr172 within the AMPK activation loop, both basally in cancer cell lines and in 
response to cytokine stimulation. Thr172 phosphorylation of AMPK is well-characterized to 
increase the activity of AMPK and to phosphorylation of downstream AMPK targets. By 
understanding the mechanism of IKK-mediated AMPK activation, I was able to devise a strategy 
for exploiting a metabolic weakness of LKB1 deficient lung cancers, which involved combining 
an IKK inhibitor with the mitochondrial complex I inhibitor phenformin. In Chapter 3, I 
characterized the mechanism whereby the IKK-related kinase, TANK-binding kinase 1 (TBK1) 
phosphorylated a critical component of mTORC1, Raptor, which could represent a mechanism 
whereby TBK1 promotes autophagy.  
Overall, the work presented here adds to our understanding of the mechanisms of how 
inflammation can regulate metabolism. Knowledge of these mechanisms will hopefully shed new 
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1. CHAPTER 1: INTRODUCTION 
 
 
1.1 Introduction to the IKK family of kinases.   
 
In the NF-κB signaling pathway, the canonical IKK complex was initially described as the 
kinase responsible for the inducible phosphorylation of IκBα1-4, which in turn leads to its 
ubiquitination and proteasomal degradation5.  Upon degradation, IκBα can no longer inhibit 
p50-p65/RelA, which allows this heterodimer to enter the nucleus and drive transcription of a 
variety of genes4. While the role of IKK in the NF-κB pathway has been extensively studied (for 
further review of this pathway see Hayden and Ghosh6), it is now appreciated that IKK also 
phosphorylates other substrates that are not involved in NF-κB mediated transcription 7 (and see 
below).  
The canonical IKK complex consists of two catalytic protein kinase subunits, IKKα and 
IKKβ, as well as a scaffold/substrate specificity factor known as IKKγ or NEMO 1,2.  Like many 
kinases, IKKα and IKKβ are activated by phosphorylation of critical residues in their activation 
loops. Activation of IKK can either be accomplished by an upstream kinase, such as TAK1, or 
by trans-autocatalytic phosphorylation8. The canonical IKK complex is activated by various 
inflammatory cytokines, such as IL-1β and TNF-α, as well as pathogen-associated molecules 
such as LPS, and downstream of oncogenic factors such as RAS. 6  Roles for IKK in promoting 
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cancer have been described, controlling both NF-κB-dependent and –independent oncogenic 
mechanisms.  
In addition to the canonical IKK complex, there exists the so-called non-canonical IKK 
complex that is comprised of IKKα homodimers, lacking both IKKβ and NEMO (see Fig.1.1). 
This complex is activated by the NF-κB inducing kinase (NIK), which is induced by stimuli such 
as CD-40 or RANK ligand9. There are two other kinases in the IKK family of kinases: IKKε and 
TANK-Binding Kinase 1 (TBK1). These kinases are most well studied for their ability to 
stimulate the production of interferon genes by phosphorylation of IRF3 and IRF7, especially in 
the innate immune system. However, recent studies indicate that these kinases play critical roles 
in the regulation of cellular growth and metabolism and both are linked with cancer.  
 
1.2 Activation and Regulation of the IKK kinases.   
Like other kinases, the IKK kinases are activated by phosphorylation of serine residues 
within their activation loops1. The activation of the canonical IKK complex is most well studied 
in response to the cytokines TNF-α and IL-1β. Upon engagement of these ligands to their 
respective receptors, the canonical IKK complex is brought into proximity with the TGF-β 
Activated Kinase 1 (TAK1), and TAK1 phosphorylates two key activation loop serines 177 and 
181 in IKKβ and the analogous residues in IKKα within the canonical IKK complex.  IKKα and 
IKKβ can also be transautophosphorylated in this complex and may also be activated by other 
upstream kinases such as MEKK310.  
The non-canonical IKK complex is activated by phosphorylation via another upstream 
kinase, the NF-κB Inducing Kinase (NIK)9. In an unstimulated cell, NIK is continuously 
synthesized and rapidly degraded by the proteasome. However, stimuli such as lymphotoxin B1 
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or RANK ligand lead to the stabilization of NIK, which in turn promotes phosphorylation of 
IKKα homodimers in their activation loops.  Interestingly, NIK is phosphorylated by IKKa to 
limit its activity11.  
TBK1 activity is stimulated by phosphorylation of S172 by an autocatalytic activity or by 
phosphorylation through ULK1, which is downstream of AMPK (and see below)12. IKKε is also 
regulated by phosphorylation of an analogous residue in its kinase domain. However, while 
TBK1 is thought to be constitutively expressed, expression of IKKε mRNA is increased in 
response to certain stimuli13.  
While the activation of the IKK kinases in response to cytokines and TLR ligands is 
relatively well established, much less is known about how IKK activity responds to nutrient 
availability and growth signals.  
For growth signals, such as insulin, Akt was shown phosphorylate IKKα, and this was associated 
with the induction of IKK activity. Serum and other growth signals can also lead to the induction 
of IKK activity14.  
In addition to growth signals, the activation of IKK is also observed with changes in nutrient 
status. Total nutrient deprivation15, as well as the withdrawal of the individual amino acids 
leucine16 and glutamine,17 have all been associated with the induction of IKK activity.   Nutrient 
stress may be accompanied by an increased in reactive oxygen species, which are known to 
activate IKK.  Other changes in nutrient status are known to inhibit IKK activity. For example, 
the ATP/AMP sensor AMPK is known to have anti-inflammatory functions in part by reducing 
IKK activity18.  IKK can be activated through O-linked β-N-acetylglucosamine modification, 
which occurred following the loss of p53 function and changes in glucose metabolism19.  
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The way that IKK and IKK related kinase recognize substrates and the factors that cause 
them to phosphorylate one substrate over another is still an open area of research. For the 
canonical IKK kinases, substrate recognition likely occurs through NEMO, which can act as a 
substrate specificity factor20 TBK1 and IKKε are often brought into proximity with their 
substrates by adaptor molecules such as STING or MAVS21.  
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Figure 1.1 Comparison of the Canonical and Non-Canonical IKK Complex 
 
Figure 1.1: This diagram shows that composition and mechanism of activation for the canonical 
and non-canonical IKK complexes. The canonical IKK complex contains two kinase catalytic 
subunits, IKKα and IKKβ as well as the scaffold and specificity factor NEMO. This complex is 
activated when stimuli such as IL-1 or TNF stimulate the formation of K63-linked and linear 
ubiquitin chains, and these chains bring the IKK activating kinase, TAK1, into proximity with 
the IKK complex, which in turn allows for phosphorylation of the IKKβ activation loop serines. 
The non-canonical IKK complex consists exclusively of IKKα homodimers. This complex is 
activated when stimuli such as BAFF, CD40 and RANK ligand induce the stabilization of NIK, 
which in turn has a high level of activity towards IKKα homodimers.  





















1.3 Cell Growth and Metabolism 
An essential prerequisite for cell division is an increase in the biomass in the cell. Before 
committing to increasing biomass, cells must sense whether there is a sufficient amount of 
energy and nutrients (primarily ATP and amino acids). In multicellular organisms, the decision 
for individual cells to grow or not to grow must be coordinated between all of the cells in the 
body. Examples where a coordinated growth pattern is necessary, include development, 
inflammation and tissue repair.  Altered growth signaling pathways are often associated with 
diseases such as cancer, obesity, diabetes and pathogen infection. Therefore, understanding 
growth signaling pathways has important consequences for understanding normal human biology 
as well as the progression of diseases.  
Concerning nutrient and energy status, the decision to grow is relatively straightforward: if 
the cell has sufficient levels of nutrients and energy it can grow; otherwise, no growth can occur. 
In contrast, many biological processes that are carried out by multicellular organisms have more 
nuanced growth demands that require more complex signaling processes. For example, during 
viral pathogen infection, the organism benefits by stimulation of growth and proliferation of 
immune cells but by the limitation of growth and division of cells infected by the virus. Thus a 
signal is necessary that stimulates the growth of specific cells and inhibits the growth of others.  
Various signaling molecules have evolved to detect these signals and to transduce them to 
promote the appropriate balance of catabolism and anabolism for a given stimulus. The two 
major nutrients that a cell requires to grow are ATP and amino acids. A multitude of sensors for 
the presence of amino acids converge on the Ragulator complex22 and the sensor for ATP levels 
is the AMP-activated protein kinase (AMPK)23,24.   
For more complex biological processes, numerous signaling pathways exist that can 
transduce a wide variety of stimuli into a coordinated physiological response, which results in 
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either anabolism or catabolism.   While growth signaling can be quite complex, several essential 
signaling nodes integrate many different signals: mTOR, AMPK, and AKT. As mentioned 
earlier many of the growth signaling cascades converge on the mTOR pathway, which has been 
extensively reviewed elsewhere25.  Briefly, in response to insulin and other growth hormones and 
cytokines, the Phosphoinositde 3-kinase (PI3K) catalyzes the creation of phospholipids at the 
plasma membrane which leads to the activation of the kinase Akt. Akt inhibits TSC2 by direct 
phosphorylation, which in turn relieves the inhibition of mTORC1 by the GTP binding protein 
Rheb. Amino acids and ATP also regulate mTOR. When there are sufficient levels of amino 
acids present, the Ragulator complex promotes mTOR signaling. AMPK on the other hand, 
which is potently activated by an increase in the ADP/ATP ratio, inhibits mTOR activity.  
Insulin is the hormone that indicates to cells that there is sufficient glucose in the 
bloodstream. Treatment of cells with insulin potently induces glucose uptake and can promote 
cellular growth. An important consequence of stimulation of insulin is the induction of the 
PI3K/Akt pathway26. The PI3K/Akt is activated by agonists of the insulin receptor, insulin, and 
insulin-like growth factor, as well as by other growth factors27.  
These various signals often converge on the mechanistic target of rapamycin (mTOR) 
signaling pathway. When this pathway is turned on, cells stimulate different growth processes, 
notably protein synthesis. The kinase mTOR exists in two complexes mTORC1 and mTORC2. 
mTORC1 phosphorylates 4EBP1 and p70S6K to stimulate protein synthesis by mTOR. In 
contrast turning off mTORC1 potently induces a process of intracellular lysosomal degradation 
known as autophagy. Autophagy has the effect of recycling intracellular proteins and organelles. 
Induction of autophagy allows cells to survive periods when nutrients are scarce28. mTORC2 on 
the other hand phosphorylates Akt, SGK, and PKC.  
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1.4 Beyond Inflammation: IKK and IKK related kinases regulate growth, metabolism, 
and autophagy.  
 
An emergent regulator of growth signaling pathways is the IKK family, which is well known 
for their role inflammation. Inflammation is rapidly becoming appreciated as a critical regulator 
of growth signaling. The IKK family of kinases is now recognized to be a crucial mediator of the 
cross-talk between inflammation and growth signaling. They regulate cellular growth and 
metabolism by phosphorylation of various protein substrates. IKK family members are known 
for promoting pro-survival responses. IKK mediated regulation of cellular growth and 
metabolism may be a way to ensure that cells have the proper metabolism to survive their 
specific situation.  
While the role of the IKK family members in promoting inflammatory cytokine production 
via NF-κB and IFR3/7 dependent transcription has been extensively studied, it is now 
appreciated that these kinases phosphorylate other substrates that are not directly involved in the 
regulation of NF-κB or IRF 3/7 transcription (see Fig. 1.2).20  One primary function of these 
kinases is to mediate the cross-talk between inflammation and cell growth or autophagy. 
There is a clear link between inflammatory states and altered metabolism. However, the type 
of metabolic modification and the consequences of the metabolic changes are highly context 
dependent.  For instance, the inflammatory cytokine TNF-α, a potent inducer of canonical IKK 
activity was also known as “cachexin” because it induced an extreme form of catabolism that 
manifested in wasting in cancer patients29. Obesity in humans and mice is accompanied by 
inflammation, manifested by up-regulation of TNF-α and other inflammatory cytokines such as 
IL-6 and activation of local tissue macrophages, which contributes to insulin resistance 30.  
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These early findings that TNF-α, a well-known inducer of IKK activity, could play a role in 
both cancer wasting and obesity likely led researchers to study the effects of IKK on insulin 
signaling and metabolism. Indeed early studies in mice indicated that IKK induces insulin 
resistance in vivo, providing some of the first evidence that IKK played a vital role for in the 
cross-talk between the inflammatory and metabolic signaling pathways. 31,32 33 Many reports 
have now demonstrated that all of the members of the IKK family can play an essential role in 
regulating metabolism in various contexts. In certain situations, the IKKs appear to promote 
growth, and in others, it seems to promote autophagy. For instance, IKKβ is known to inhibit 
Akt signaling by phosphorylation of the p85 subunit of PI3K, but also to promote mTOR 
signaling by phosphorylation of TSC1.  This seemingly paradoxical role for IKK likely reflects 
the importance of the context for the IKK activity or could reflect mechanisms to finely tune the 
amount of anabolism and catabolism that occur in the cell.   
Below I will describe the some of the IKKα and IKKβ mediated phosphorylation events that 
could explain some of the metabolic phenotypes observed above (see Fig. 1.3).  
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Figure 1.3 Diagram of how IKKα/β promote growth signaling or autophagy 
 
Figure 1.3: Diagram of the major IKKα/β driven phosphorylation events in the growth and 
autophagy pathways. Green arrows indicate that the phosphorylation event is associated with the 































1.5 Promotion of growth signaling by IKKα and IKKβ through phosphorylation of 
substrates in the Akt/mTOR pathway 
 
IKKβ promotes mTOR signaling by phosphorylation of TSC1.  
The tuberous sclerosis 1 (TSC1) gene encodes a tumor suppressor protein that is part of a 
critical complex with tuberous sclerosis 2 (TSC2), which is well-known for its role in mTOR 
regulation34.  TSC1 is required for stabilization of TSC2 by preventing its degradation by the 
ubiquitin-proteasome system. 35,36  TSC2 contains a GTPase Activating Protein (GAP) domain 
that primarily promotes the GTPase activity of the Rheb, which results in inhibition of mTORC1. 
37-39 Phosphorylation of the TSC1-TSC2 complex is a way to integrate a diverse set of signals 
(including growth factors, cytokines, and cellular stress) to the mTOR complex, with many 
different upstream kinases acting to phosphorylate the complex34.  IKKβ was shown to inhibit 
the TSC1-TSC2  complex and thus promote mTOR signaling downstream of TNF-α40. IKKβ 
specifically phosphorylated TSC1 at serines 487 and 511. Phosphorylation of these two serine 
residues served to stabilize TSC1, as phosphomimetic mutations in serine 487 and 511 
significantly decreased the half-life of the TSC1 protein. The authors also show that 
phosphorylation of these two serine residues contributes to the formation of the TSC1/TSC2 
complex. By inactivating a negative regulator of mTOR, IKKβ could efficiently promote 
mTORC1. Our group, however, has found that this phosphorylation of TSC1 only occurred in 
certain cell lines41.  
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IKKα can also promote growth by phosphorylation of mTOR at serine 1415  
Our group found that IKK is required for mTOR activation downstream of AKT in prostate 
cancer cells with a loss of the tumor suppressor PTEN and downstream of insulin and TNF-
α41,42. Based these studies, our group concluded that IKKα within the canonical IKK complex 
plays a more critical role than IKKβ with respect to mTOR signaling, especially in prostate 
cancer cells that have constitutive Akt activation due to a loss of the tumor suppressor PTEN. 
Our group also demonstrated that IKKα phosphorylates mTOR at serine 1415 and that this 
phosphorylation promoted mTOR association with Raptor and mTORC1 mediated 
phosphorylation of p70-S6K 43. IKKα promotes Akt activation by increasing mTORC2 activity; 
however, the mechanisms by which this occurs are still unknown44. Importantly, mTOR was 
required for regulation of NF-κB downstream of AKT45. 
It is interesting that IKKα and IKKβ can both positively regulate mTOR signaling, by direct 
phosphorylation of two distinct components of the pathway. The canonical IKK complex can 
both inactivate a negative regulator of mTOR and also directly promote mTOR by 
phosphorylation of the kinase domain itself. This redundancy may be a way to ensure that mTOR 
is activated if either IKKα or IKKβ is inhibited.  
 
IKK inhibits CYLD (cylindromatosis)-a negative regulator of Akt activation by growth factors 
TRAF6 mediated Akt ubiquitination is required for Akt membrane localization and 
activation46. TRAF6 specifically adds K63-linked polyubiquitin chains to its targets. CYLD is a 
lysine 63 deubiquitinase that deubiquitinates Akt in serum-starved cells, thus negatively 
regulating its activity47.  CYLD also negatively regulates NF-kB signaling through its 
deubiquitinase activity.48 The canonical IKK complex phosphorylates CYLD to inhibit its 
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deubiquitinase activity. 49   It is, therefore, possible that IKK could promote Akt activity by 
inhibiting CYLD mediated Akt deubiquitination, although this relationship needs to be further 
explored. NEMO is required for CYLD mediated phosphorylation, but IKKα and IKKβ have 
similar activities towards CYLD.   
 
IKK down-regulates FOXO3a by phosphorylation of Serine 644.   
In addition to directly promoting Akt pathway signaling components, IKK and Akt also share 
a common effector substrate: FOXO3a. In this instance, IKK can functionally mimic Akt activity 
in the absence of Akt activity. Akt phosphorylates several of the FOXO transcription factors26. 
Phosphorylation of these sites by Akt creates 14-3-3 binding sites leads to their exclusion from 
the nucleus, thus preventing them from activating transcription. 50-53 In addition to its exclusion 
from the nucleus, Akt phosphorylation could lead to proteasomal degradation of FOXO3a54.   
IKK also inhibits FOXO3a by phosphorylating serine 644, which serves to either destabilize 
FOXO3a or exclude it from the nucleus. In acute myeloid leukemia, IKK could exclude 
FOXO3a from the nucleus even when Akt was inhibited. 55 This exclusion from the nucleus was 
dependent on phosphorylation of S644.  
However, instead of creating a 14-3-3 binding site as is the case in Akt mediated inhibition of 
FOXO transcription factors, phosphorylation at serine 644 by IKK leads to ubiquitination and 
proteasome-mediated degradation56. IKK mediated FOXO3a regulation is thought to be 
independent of Akt, as IKK could still repress FOXO3a transcription on a mutant of FOXO3a 
that had all of the Akt dependent serine phosphorylation sites mutated to alanine. Interestingly, it 




IKKβ phosphorylates XBP-1 to promote insulin sensitivity 
One report indicated that in a mouse model of chronic liver inflammation driven by liver-
specific expression of constitutively active IKKβ, the mice surprisingly showed an improvement 
in glucose homeostasis. 58 This observation was surprising as many others had implicated IKKβ 
in insulin resistance and poor glucose homeostasis. Mechanistically, the authors of this report 
linked this improvement in glucose homeostasis with the endoplasmic reticulum stress response, 
which is regulated by XBP1.  Constitutively active IKKβ increases the stability of XBP1 by 
phosphorylation of Thr48 and Ser148. IKKβ interacted with XBP in lean mice but not in obese 
mice and was associated with higher levels of endoplasmic reticulum stress due to the lack of 
XBP1 protein. These defects could be rescued by overexpression of constitutively active IKKβ 
in the livers of obese mice. This result would indicate that activation of IKKβ in the livers of 
obese patients could promote healthy glucose homeostasis.  
1.6 IKK can also oppose mTOR/Akt signaling 
• IKKβ inhibits insulin receptor signaling by phosphorylation IRS-1 and the p85 subunit of 
PI3K.  
As stated in the introduction, obesity often results in low-level, chronic inflammation and this 
inflammation leads to insulin resistance, which often precedes diabetes. IKKβ and possibly 
IKKα can inhibit insulin signaling by phosphorylation of IRS-1 and the p85 subunit of PI3K.  
The Insulin Receptor(IR) and IGF-1 Receptor (IGFR) are receptor tyrosine kinases59. Upon 
binding of their respective ligands, IR and IGFR phosphorylate a family of proteins in the Insulin 
Receptor Substrate (IRS) family, including IRS-1 through IRS-6. Phosphorylation of these 
proteins creates a binding scaffold for SH2-domain-containing protein that leads to activation of 
the PI3K/Akt signaling pathway.  In contrast to tyrosine phosphorylation, serine/threonine 
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phosphorylation is thought to downregulate IRS-1 both by preventing tyrosine phosphorylation 
and by promoting its degradation60.  
Treatment of cells with insulin induces phosphorylation of IRS-1 Serine 312, and this 
phosphorylation can lead to its degradation, which serves as a negative feedback mechanism for 
insulin signaling.61. Chronic TNF-α stimulation can also lead to serine phosphorylation and 
degradation of IRS-1, and this lack of IRS-1 protein is associated with insulin resistance, as IRS-
1 can no longer transmit signals from the insulin receptor.  
To understand how IKK regulates insulin resistance, Gao et al. 62 showed that IKK could 
directly phosphorylate IRS-1 Ser 312. They demonstrated that induction of IKK activity by TNF-
α and calyculin-A was correlated with induction of IRS-1 Ser 312 phosphorylation in HepG2 
liver cancer cells. The authors focused on IRS-1 Serine 312 as there is an abundance of 
functional data indicating the importance of that particular phosphorylation site. However, the 
authors also suggest that there may be other IKK dependent phosphorylation sites in IRS-1. The 
functional relevance of these different phosphorylation sites remains to be determined.  
One may speculate that this could serve as a mechanism whereby TNF-α treated cells restrict 
pathogen replication by making cells insensitive to insulin-induced glucose uptake. This would 
prevent intracellular pathogens from using glucose and thus starving them of the energy that they 
would need to replicate properly.  
IKKα and IKKβ immunoprecipitated separately from HEK293T cells had a similar kinase 
activity towards recombinant IRS-1. However, since IKKα and IKKβ are frequently found in 
complexes together, it is possible that these immune complexes contained both IKKα and IKKβ. 
It is therefore impossible to know which kinase is responsible for direct IRS-1 phosphorylation. 
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Future studies are necessary to determine whether the canonical or non-canonical IKK complex 
can phosphorylate IRS-1.  
Work from our group previously published that IKK was involved in feedback inhibition of 
PI3K by phosphorylation of the p85 subunit of PI3K 16. In this study both IKKα -/- and IKKβ-/- 
MEFs failed to efficiently shut off Akt S473 phosphorylation after starvation of all nutrients in 
Hank’s Balanced Salt Solution. Treatment of the MEFs with the NEMO Binding Domain 
Peptide (NBD) that is known to disrupt the canonical IKK complex also prevented starvation 
induced Akt shut-off. However, both IKKα and IKKβ were able to phosphorylate p85-PI3K at 
Ser690 efficiently. Phosphorylation of this site blocked p85 phosphotyrosine binding, thus 
preventing it from interacting with growth factor receptors. All of the data presented above led to 
the model whereby both IKKα and IKKβ within the canonical IKK complex phosphorylate p85 
to downregulate Akt phosphorylation in response to starvation.  
 
IKKβ phosphorylates RPS3 
The Ribosomal Protein S3 (RPS3) is a component of the 40S ribosome but contains some 
non-ribosomal activities, including acting as a specificity factor for NF-κB transcription factor 
complexes.63,64 IKKβ phosphorylates RPS3 at S209, which in turn induces its translocation into 
the nucleus64. Nuclear RPS3 was able to function to alter which promoters are bound by NF-κB 
transcription factors. While there is an apparent effect on nuclear translocation, it will be 
interesting in the future to determine what effect, if any, RPS3 S209 phosphorylation has on 
protein translation, which is an important output of mTOR regulation.  
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IKKβ phosphorylates PFKFB3 Ser269 to promote metabolic adaptation to glutamine 
deprivation.  
In addition to phosphorylation of protein substrates that transduce extracellular signals, IKKβ 
also phosphorylates PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) which is 
a metabolic enzyme to adapt to periods of glutamine deprivation.17 In this case, IKKβ inhibits 
aerobic glycolysis, which is the type of metabolism favored by rapidly growing cells.  
PFKFB3 is a crucial driver of aerobic glycolysis. In the case of glutamine deprivation, 
aerobic glycolysis does not promote survival. If glutamine starved cells fail to switch from 
aerobic glycolysis to oxidative phosphorylation, they die. During glutamine deprivation, IKKβ 
promoted oxidative phosphorylation by promoting phosphorylation of PFKFB3, which had the 
effect of inhibiting the activity of this enzyme. This study somewhat contradicts others in that 
they reported that IKK deficiency leads to an increase in aerobic glycolysis, whereas others have 
observed that IKK deficiency limits the Warburg effect.  For example, in cancer cells, IKKβ was 
shown to play an essential role in controlling Warburg metabolism and glucose import by 
regulating NF-κB dependent induction of metabolic genes. 65  
 
1.7 IKKα and IKKβ can promote autophagy 
 
Turning off mTORC1 potently induces a process of intracellular lysosomal degradation 
known as autophagy. Autophagy has the effect of recycling intracellular proteins and organelles. 
Induction of autophagy allows cells to survive in nutrient stressful conditions, such as during low 
concentrations of amino acids or ATP28.  IKK family proteins are directly linked with control of 
autophagy.  
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In 2010 Criollo et al. 15 demonstrated that IKK was involved in the induction of autophagy in 
response to several known autophagy inducers including starvation media and rapamycin. This 
group showed that overexpression of constitutively active IKK was sufficient to promote the 
induction of autophagy and that this induction required the AMP-activated protein kinase 
(AMPK). Importantly, overexpression of constitutively active IKK was adequate to promote 
AMPK activation in HeLa cells, which lack the major AMPK activating kinase LKB1. Our 
group expanded on this work to demonstrate that IKK could directly phosphorylate AMPK in its 
activation loop and promote its activity (see below and Chapter 2).  
IKKα stabilizes the autophagy protein Atg16L by phosphorylation.  
In a mouse model of colitis induced inflammation, IKKα phosphorylates Atg16L1 at serine 
278 to stabilize it.66 Atg16L is an essential autophagy protein 67. Interestingly, in this study, the 
author’s found that knockout of IKKα but not p100/NF-κB2 in intestinal epithelial cell 
exacerbated colitis symptoms. This observation indicates that IKKα has some functions in colitis 
that are independent of activating the non-canonical NF-κB pathway. The authors in this study 
did not relate their findings to autophagy, however, and their conclusions were more associated 
with the ER-stress response pathway.  
A naturally occurring mutation in Atg16L1, which prevents its Caspase-mediated 
degradation, is associated with Crohn’s disease. The authors of this study thus hypothesized that 
IKKα might be exacerbating colitis in this model by affecting Atg16L stability. While the 
authors of this study found that phosphorylation of Atg16L1 by IKKα could promote its 
stability, the authors did not look at the effects of this phosphorylation on the process of 
autophagy. One might hypothesize that increased Atg16L stability would increase autophagic 
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flux and an important future direction will be to determine whether this phosphorylation site can 
enhance or inhibit autophagy.  
Figure 1.4 Diagram of how TBK1/IKKε promote growth signaling or autophagy 
 
Figure 1.4: Diagram of the major TBK1/IKKε driven phosphorylation events in the growth and 
autophagy pathways. Green arrows indicate that the phosphorylation event is associated with the 

































1.8 Regulation of growth signaling pathways via TBK1/IKKε 
The IKK related kinases TBK1 and IKKε are also known to be important regulators of cell 
growth and autophagy. Similar to IKKα and IKKβ, TBK1 and IKKε can also promote cell 
growth or induce autophagy depending on the context.  
Several lines of work now indicate that TBK1 and IKKε are induced in mouse models of 
obesity and that they play a significant role in the pathology of this disease. IKKε and TBK1 
expression are induced in mouse models of obesity and IKKε regulates energy expenditure in 
this model68. Deletion of IKKε in mice prevents weight gain caused by high-fat diet and 
increases insulin sensitivity and obesity induced inflammation. Knockout of TBK1 in adipocytes 
also improved the clinical features of obesity in mice. A small human clinical trial of a 
TBK1/IKKε inhibitor, Amlexanox, in diabetic patients showed a significant decrease in markers 
of the disease and was able to restore insulin sensitivity in a select group of the patients on the 
trial. In addition to diabetes and obesity, IKKε was shown to be involved in glucose 
reprogramming in pancreatic ductal adenocarcinoma, and TBK1 was shown play a significant 
role in the regulation of Akt/mTOR signaling in lung cancer cell lines69. 70 
Below I will describe the some of the TBK1 and IKKε mediated phosphorylation events that 
could explain some of the metabolic phenotypes observed above (see Fig. 1.4) .  
  
TBK1/IKKε  can promote Akt activation by direct phosphorylation  
As mentioned in the introduction, a key effector of PI3K activation is the kinase Akt. Akt 
kinase activity is activated by phosphorylation of Thr308 and Ser473.71  Two reports have been 
published that demonstrate that TBK1 and IKKε can directly phosphorylate and activate Akt. 
72,73   One study reported that in MEFs, EGF and LPS, but not insulin induced Akt activation was 
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TBK1 dependent. TBK1 was able to phosphorylate both Akt Thr308 and Ser476. As for the 
relevance of TBK1 mediated Akt regulation in cells other than MEFs, the same groups recently 
published that in cancer cell lines, the role of TBK1 in regulating Akt is dependent on many 
factors, including whether or not a cell has undergone an epithelial to mesenchymal transition69. 
Another study utilizing TBK1/IKKε double knockout MEFs found that both kinases were 
required for activation of Akt by a wide range of stimuli, including insulin73.  This difference 
between TBK1 -/- and TBK1/IKKε double knockout MEFs for only certain stimuli, indicates 
that these two kinases may have both redundant and non-redundant roles with respect to Akt, 
dependening on the stimulus.  
 
IKKε inhibits GSK3α Serine 21 to promote mTOR/AKT.  
In addition to direct phosphorylation, IKKε was shown to promote Akt activation by negative 
regulation of an AKT suppressor, GSK3α. IKKε was shown to phosphorylate GSK3α Ser21, 
which interestingly is also a substrate for Akt. Gullen et al. noted that IL-1β induced PI3K/Akt 
independent GSK3α Serine 21 phosphorylation, a phosphorylation site known to inhibit GSK3α 
kinase activity 74. The authors found that in the context of IL-1β signaling in Th17 cells, GSK3α 
suppresses Akt activity by phosphorylation of Akt Thr312, near Akt Thr308, a site well-
characterized to promote Akt activity. Akt Thr312 is located within the region of Akt required 
for substrate recognition. Phosphorylation of Thr312 was predicted to inhibit substrates from 
entering the Akt active site.  IKKε inactivated GSK3 by phosphorylation of serine 21, which 
relieved inhibition on Akt and had the overall effect of promoting Akt/mTOR activation. This 
study focused on Th17 cells, so it will be interesting in the future to learn if this mode of 
regulation can occur in other cell types or contexts. 
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TBK1/IKKε can promote mTOR activation by phosphorylation of Ser 2159 in the mTOR 
activation loop.   
Phosphorylation of mTOR at serine 2159 in the kinase domain was shown to be sufficient to 
promote mTOR kinase activity,75 and knock-in mice with an mTOR Serine 2159 to Alanine 
mutation showed defective mTOR signaling in vivo. Interestingly, Insulin but not EGF was 
capable of inducing this phosphorylation site (mTOR S2159), in a TBK1/IKKε dependent 
manner. TBK1 and IKKε were identified in a screen for kinases that could directly 
phosphorylate this site in vitro.76 Of the wide panel of kinases tested, TBK1 and IKKε showed 
the most robust levels of activity towards this site, indicating that these are likely to be the most 
significant kinases for mTOR Ser2159 in vivo.  Overall, these studies suggest that TBK1/IKKε 
can promote mTOR activity by phosphorylation of Ser2159, but it should be noted that there is 
also a significant amount of data to indicate that TBK1/IKKε also inhibit mTOR (see below). It 
is interesting to note that IKKα can also phosphorylate mTOR to promote mTORC1 signaling 
and an interesting future direction will be to study the cross-talk between IKKα and TBK1/IKKε 
with respect to this pathway.  One group described a mechanism whereby TBK1 inhibited the 
upstream IKKα activating kinase NIK by direct phosphorylation77.  
 
TBK could promote mTOR signaling by inhibition of AMPK activity by Ser459 and Ser 476 
phosphorylation  
A recent study also indicates that TBK1 can directly inhibit AMPK by promoting 
phosphorylation of AMPK and Ser459 and Ser47678. Phosphorylation of these sites was 
associated with a decrease in AMPK activity as measured by phosphorylation of AMPK Thr172. 
In cell-free kinase assays, TBK1 was unable to phosphorylate AMPK, and the authors speculated 
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that another factor was required in the reaction for TBK1 to promote efficient phosphorylation of 
AMPK. Future studies are necessary to determine the identity of this factor and to determine 
whether TBK1 can directly phosphorylate AMPK. Interestingly, AMPK could promote TBK1 
phosphorylation by promoting ULK1 mediated phosphorylation of TBK1 Ser172. Therefore, 
TBK1 mediated AMPK inhibition represents a feedback mechanism on AMPK.  
In contrast to TBK1 and IKKα, which both phosphorylate mTOR to promote its activity, 
IKKβ and TBK1 appear to exert opposite effects on AMPK by direct phosphorylation.  Our 
work in Chapter 2 will describe in detail how IKKβ promotes AMPK Thr172 phosphorylation.   
 
TBK1 phosphorylates the EXOC8 to promote glucose uptake by trafficking GLUT4 to the plasma 
membrane.  
Upon stimulation with insulin, AKT induces glucose uptake by causing a rapid translocation 
of the glucose transporter GLUT4 to the plasma membrane. The exocyst complex controls 
trafficking of GLUT4 to the plasma membrane in response to insulin. 79 A recent report indicated 
that TBK1 phosphorylates a component of the exocyst, EXOC8, to promote Glut4 trafficking to 
the cell membrane in response to insulin. 80 Insulin-stimulated glucose uptake in 3T3-L1 
adipocytes was attenuated by knockdown or inhibition of TBK1 but not by knockdown of either 
IKKα, IKKβ or IKKε. This difference in phenotype between the different IKK family members 
indicates that while the IKK and IKK related kinases often share overlapping substrates, they do 
not have completely redundant functions.    
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1.9 Inhibition of Akt/mTOR signaling via TBK1/IKKε 
TBK1 inhibits the Insulin Receptor by phosphorylation of Serine 994.   
In addition to promoting Insulin signaling by activation Akt, TBK1 and IKKε are also known 
to contribute to insulin resistance81. TBK1/IKKε could contribute to insulin resistance by direct 
inhibition of the Insulin Receptor (IR). In addition to serine phosphorylation of IRS proteins as 
described earlier, serine phosphorylation of the IR itself is also associated with inactivation of 
the receptor. Among the serine residues that are found to be phosphorylated is serine 994. 
Mutation of this serine to alanine increased the tyrosine kinase activity of the insulin receptor 
when expressed in HEK 293 cells82. TBK1 activity was associated with Insulin Receptor 994 
phosphorylation in vivo. TBK1 displayed activity towards a peptide that contained Serine994, 
but not a peptide in which Serine994 was mutated to alanine in a cell-free kinase assay. 83 These 
experiments indicate that TBK1 could inhibit the tyrosine kinase activity of IR by 
phosphorylation of IR Ser994.  
 
Roles for TBK1 in down-regulating mTOR and promoting Autophagy 
Critical signaling pathways in response to nutrients or nutrient deprivation integrate signaling 
which leads to regulation of mTORC1 and autophagy.  These responses play critical roles in 
promoting growth or promoting autophagy for survival.  Crosstalk between mTORC1 and 
autophagy signaling have been extensively reviewed84. Several studies have linked TBK1 with 
regulation of mTORC1 as well as AMPK, an upstream regulator of the autophagic response (see 
below).  
In cancer, TBK1 mediated suppression of mTOR was linked to prostate cancer dormancy. In 
this study overexpression of wt but not kinase-dead TBK was sufficient to block mTORC1 
activity as measured by p70S6K phosphorylation85. In a model of chronic innate immune 
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activation induced by knockout of the Three-prime repair exonuclease 1 (TRex1), which mimics 
chronic STING activation, TBK1 was also linked to suppression of mTORC1 activity86.  
The SMRC8 gene product is expressed in neurons and is associated with amyotrophic lateral 
sclerosis and frontotemporal dementia. Interestingly loss of function TBK1 mutations were 
found in patients with the same disease. 87,88SMRC8 was found in a complex with the autophagy 
initiating kinase Ulk1 and is described to be important for autophagy initiation89. It was found 
that TBK1 phosphorylates this protein and that this phosphorylation is required for autophagy 
initiation.90 Recent work also indicates that ULK1 can act as an upstream kinase for TBK1 
Ser17278. SMRC8 may act as a recruitment factor, bringing ULK1 in close proximity to TBK1 to 
promote TBK1 Ser172 phosphorylation.  Pili et al demonstrated that TBK1 is required for 
autophagosome maturation in response to several inflammatory stimuli91. TBK1 phosphorylated 
the autophagy cargo adaptor p62 (SQSTM1) and this was required for p62’s functions in 
promoting autophagy. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and 
promotes selective autophagy of damaged mitochondria92. 
1.10 Introduction to AMPK (adapted from Antonia and Baldwin, Science Signaling 2018) 
 
AMPK (5' AMP-activated protein kinase) is a highly conserved master energy-sensing kinase 
that phosphorylates a variety of substrates to promote ATP conservation. 24,93 The most well-
characterized effector substrate of AMPK is Acetyl-Co-A Carboxylase (ACC), which promotes 
fatty acid biosynthesis94. AMPK phosphorylation of ACC inhibits its activity and therefore 
inhibits fatty acid synthesis, a process that consumes large amounts of ATP. AMPK also 
phosphorylates ULK1 to promote autophagy95,96, and Raptor to inhibit mTORC1 signaling97. 
Many other substrates have been defined for AMPK, and in general phosphorylation of these 
substrates serves the function of increasing the levels of ATP in the cell.  
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AMPK opposes inflammation and NF-κB signaling 
In addition to its well-defined role in promoting energy conservation, AMPK is also known 
to modulate inflammation98,99.  Evidence primarily comes from that fact that AMPK agonists can 
reduce inflammation markers in certain inflammatory disease models100,101. Some have 
suggested that AMPK regulates NF-κB indirectly through modulation of  PCG-1α102 or 
SIRT1.103,104  However, it remains possible that AMPK regulates NF-κB signaling by direct 
phosphorylation of components of the NF-κB signaling machinery.  
 
Regulation of AMPK activity 
The AMPK holoenzyme is composed of three subunits, AMPKα, AMPKβ, and AMPKγ. The 
kinase domain lies within the AMPKα subunit. AMPKγ contains nucleotide binding domains 
that bind either AMP or ATP, which allows for allosteric regulation of the enzyme. The AMPKβ 
subunit serves scaffolding and structural roles. AMPK kinase activity is regulated by 
phosphorylation of Thr172 in the kinase domain activation loop of the kinase domain in AMPKα 
and allosterically by adenosine nucleotide binding 105-107. Binding of AMP to the gamma subunit 
of AMPK induces an increase in AMPK activity, and binding of either AMP or ADP promotes 
Thr172 phosphorylation in the kinase domain by causing a conformational change in the AMPK 
holoenzyme that prevents phosphatases from accessing Thr172, which leads to an increase in the 
levels of Thr172 phosphorylation. In cell-free kinase assays, allosteric binding of AMP to the 
gamma subunit causes a 5-fold increase in AMPK activity while phosphorylation of Thr172 
causes a 100-fold increase in AMPK activity, thus Thr172 phosphorylation is the primary point 
of AMPK regulation both by adenosine nucleotides and by upstream kinases105,108,109.   
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Three kinases have been shown to phosphorylate AMPK at Thr172: LKB1 (liver kinase B1), 
CAMKK2 (calcium/calmodulin-dependent protein kinase kinase 2) and TAK1 (transforming 
growth factor-activated kinase-beta-1).  The kinase upstream of AMPK is dependent on the 
signaling cascade or specific stressor.  When the AMP/ATP ratio is increased in cells, a 
conformational shift occurs that makes Thr172 more amenable to phosphorylation by LKB, a 
robust and well-characterized AMPK kinase. 110-112  However, LKB1 is a tumor suppressor that 
is lost in many cancers, and these cancers still require AMPK for growth and survival. 113  
Stimuli such as ionomycin that lead to an increased concentration of intracellular calcium 
cause CAMKK2 to phosphorylate Thr172 114-116. Additionally, cytokines such as IL-1, TNF, and 
TRAIL lead to AMPK Thr172 phosphorylation in a TAK1-dependent manner 117,118, although 
much less is known concerning the mechanism of how TAK1 promotes AMPK Thr172 
phosphorylation.  
Role of AMPK in Cancer and Disease 
Many diseases are associated with altered metabolism and AMPK as a master energy sensor 
plays an important role in diseases such as cancer, diabetes, heart disease and pathogen infection. 
Each of the three AMPK subunits has redundant coding regions. There is an AMPKα1 and an 
AMPKα2, AMPKβ1 and AMPKβ2, AMPKγ1, AMPKγ2, and AMPKγ3. Mutations in AMPKγ2 
leads to a genetic heart disorder known as Wolf-Parkinson-White disease119.  
 AMPK loss of function mutations or deletions are rarely observed in human cancers. 
Moreover, since each AMPK subunit contains redundant coding regions, a complete loss of 
AMPK activity is almost never observed in human cancers. AMPK appears to play a dual role in 
cancer depending on the context. AMPK can promote NADPH balance and mitophagy 
(autophagic degradation of mitochondria) to favor tumor survival under metabolic stress, as is 
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frequently observed in tumors. However, AMPK can inhibit growth signaling and protein 
synthesis pathways (notably mTOR signaling) to limit tumor growth. 113 The major upstream 
AMPK activating kinase, LKB1, is a tumor suppressor that is lost in many cancers, and is 
thought to exert its tumor suppressive actions by promoting AMPK activity.120   
Since the role of AMPK in cancer is so context dependent it is critical to understand the role 







2 CHAPTER 2: IKK PROMOTES CYTOKINE-INDUCED AND CANCER-
ASSOCIATED AMPK ACTIVITY AND BUFFERS AGAINST PHENFORMIN-
INDUCED CELL DEATH IN LKB1-DEFICIENT CELLS1 
2.1 Overview 
The 5' AMP-activated protein kinase (AMPK) is a master energy sensing kinase that is 
regulated by phosphorylation of Thr172 in its activation loop.  Three kinases have been 
described to phosphorylate AMPK at Thr172: the tumor suppressor LKB1, CAMKK2 and 
TAK1.  While LKB1- and CAMKK2-mediated AMPK Thr172 phosphorylation have been well-
characterized, much less is known about TAK1-dependent AMPK phosphorylation.  An 
important target of TAK1 is IκB kinase (IKK) which controls NF-kB transcription factor 
activation.  Here, we tested the hypothesis that IKK acts downstream of TAK1 to activate 
AMPK by phosphorylating Thr172. IKK is required for AMPK Thr172 phosphorylation induced 
by IL-1β and TNF-α treatment and by TAK1 overexpression.  Additionally, IKK regulates basal 
AMPK Thr172 phosphorylation in several cancer cells independent of TAK1, indicating that 
other modes of IKK activation can lead to AMPK activation.  Mechanistically, we found that 
IKK directly phosphorylates AMPK at Thr172 and that IKK promotes AMPK Thr172 
phosphorylation independent of LKB1 expression or energy stress.  This indicates that while 
                                                
1 This chapter has been adapted from a manuscript that has been accepted for publication in 
Science Signaling The original citation is as follows: “Antonia RJ. and Baldwin AS. IKK 
Promotes Cytokine-Induced And Cancer-Associated AMPK Activity And Buffers Against 
Phenformin-Induced Cell Death In LKB1-Deficient Cells. Science Signaling 2018.  
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LKB1 activates AMPK as a sensor of energetic stress, IKK activates AMPK in response to 
extracellular inflammatory signals and through distinct pathways that activate IKK.  
Accordingly, in LKB1-deficient cells IKK inhibition caused a reduction in AMPK Thr172 
phosphorylation in response to the mitochondrial inhibitor phenformin.  This response led to 
enhanced apoptosis and suggests that IKK inhibition in combination with phenformin could be 
used clinically to treat patients with LKB1-deficient cancers.  
 
2.2 Introduction  
AMPK (5' AMP-activated protein kinase) is a master energy sensing kinase that 
phosphorylates a variety of substrates to promote ATP conservation 24,93.  AMPK appears to play 
a dual role in cancer depending on the context. AMPK can promote NADPH balance and 
mitophagy to favor tumor survival under metabolic stress, as is frequently observed in tumors.  
However, AMPK can inhibit growth signaling and protein synthesis pathways (notably mTOR 
signaling) to limit tumor growth 113.  AMPK activity is regulated by phosphorylation of Thr172 
in the kinase domain activation loop and allosterically by adenosine nucleotide binding 105-107.  
Binding of AMP to the gamma subunit of AMPK induces an increase in AMPK activity, and 
binding of either AMP or ADP promotes Thr172 phosphorylation in the kinase domain by 
causing a conformational change in the AMPK holoenzyme that prevents phosphatases from 
accessing Thr172 106,107.  In cell-free kinase assays, allosteric binding of AMP to the gamma 
subunit causes a 5-fold increase in AMPK activity while phosphorylation of Thr172 causes a 
100-fold increase in AMPK activity, thus Thr172 phosphorylation is the major point of AMPK 
regulation105,108,109,121.  Three kinases have been shown to phosphorylate AMPK at Thr172: 
LKB1 (liver kinase B1), CAMKK2 (calcium/calmodulin dependent protein kinase kinase 2) and 
TAK1 (transforming growth factor activated kinase-beta-1)93.  The kinase upstream of AMPK is 
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dependent on the signaling cascade or specific stressor.  When the AMP/ATP ratio is increased 
in cells, a conformational shift occurs that makes Thr172 more amenable to phosphorylation by 
LKB1, a robust and well-characterized AMPK kinase 110,112,122.  However, LKB1 is a tumor 
suppressor that is lost in many cancers and these cancers still require AMPK for growth and 
survival 113. This implies that other sources of AMPK activation are important in cancer.  
Stimuli such as ionomycin that lead to an increased concentration of intracellular calcium 
cause CAMKK2 to phosphorylate Thr172 114-116.  Additionally, cytokines such as IL-1, TNF and 
TRAIL lead to AMPK Thr172 phosphorylation in a TAK1-dependent manner 117,118, although 
much less is known concerning the mechanism of how TAK1 promotes AMPK Thr172 
phosphorylation.  
TAK1 is activated by inflammatory signals such as IL-1 and TNF, and in turn activates 
several downstream pathways including the NF-κB transcription factor pathway, the c-Jun N-
terminal kinase (JNK) pathway, p38 pathway and AMPK 123.  To activate p38 and JNK 
pathways, TAK1 phosphorylates mitogen activated protein kinases (MAPKs).  To activate the 
NF-κB pathway, TAK1 directly phosphorylates IκB Kinase (IKK) to promote its activity.  TAK1 
promotes NF-κB dependent transcription by directly phosphorylating IKK at serines 177 and 181 
which lie within the IKKβ activation loop 8.  The canonical IKK complex consists of two highly 
related kinases IKKα and IKKβ 1,2, and a scaffolding protein IKKγ (also known as NEMO) 20,124.  
In addition to activation by TAK1, IKK can also be activated by trans-autophosphorylation 
especially in the presence of linear ubiquitin molecules 125.  IKK was originally described as the 
kinase responsible for the inducible phosphorylation of IκBα 6.  Phosphorylation of IkBα by 
IKK leads to its rapid proteasome-mediated degradation, which in turn allows NF-κB 
transcription factors to enter the nucleus and promote transcription.  Although IKK is best known 
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for its role in promoting the NF-κB transcription activation pathway, NF-κB independent roles 
for IKK have been described 126.  The exact mechanisms that lead IKK to phosphorylate one 
substrate over another are incompletely understood, however this likely involves NEMO, which 
can act as a substrate specificity factor 20.  Among the NF-kB-independent roles for IKK is a 
role in promoting AMPK-dependent autophagy 15,20,127. Previous work demonstrated that 
expression in HeLa cells (LBK1-deficient) of a mutant IKKβ that mimics 177 and 181 
phosphorylation is sufficient to induce AMPK Thr172 phosphorylation.  This mutant IKK 
mimics constitutive phosphorylation by TAK1, thus these results suggested that IKK could play 
a role downstream of TAK1 in activating AMPK, independent of LKB115.  
In this study we explored a potential relationship between IKK and AMPK, and demonstrate 
that IKK is required for basal and cytokine-induced AMPK Thr172 phosphorylation in a variety 
of cell lines, regardless of LKB1 status.  In response to the inflammatory cytokines IL-1β and 
TNF-α, IKKβ promoted AMPK Thr172 phosphorylation downstream of TAK1.  However, we 
also identified several cancer cell lines where IKK regulates AMPK independent of TAK1.  
Since there are situations where IKK regulates AMPK independent of TAK1, we assessed 
whether IKK could directly phosphorylate AMPK.  Importantly, we found that IKK 
phosphorylates Thr172 in cell free kinase assays, promoting AMPK activity. 
The mitochondrial complex I inhibitor phenformin causes energetic stress by rapidly depleting 
ATP 128.  This leads to activation of AMPK in an LKB1-dependent manner, which in turn leads 
to energy conservation and growth arrest.  Cells that lack LKB1 undergo apoptosis in response to 
phenformin treatment, which led to the concept that phenformin could be used therapeutically to 
treat LKB1- deficient cancers 128,129.  Since IKK is shown to be important for AMPK regulation 
in LKB1-deficient cells, we asked whether IKK inhibition would further sensitize these cells to 
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phenformin.  IKK inhibition led to a decrease in AMPK Thr172 phosphorylation in LKB1-
deficient cells when treated with phenformin, which resulted in enhanced apoptosis.  These 
results suggest that a combination of IKK inhibition and phenformin treatment could be a useful 
therapeutic strategy for LKB1-deficient cancers.  
2.3 Results  
IKK is required for AMPK Thr172 phosphorylation induced by IL-1β  
Previously it was  demonstrated that two known inducers of IKK activity, IL-1 and TNF, are 
capable of increasing AMPK Thr172 phosphorylation in serum-starved HeLa cells, which lack 
the major upstream AMPK Thr172 kinase LKB1 118.  Since IL-1 is a potent inducer of IKK 
activity, we tested whether IKK is required for AMPK Thr172 phosphorylation in response to 
IL-1β.  Pre-treatment with the IKK specific inhibitor Compound A (Bay 65-1942) 130 prevented 
IL-1β from inducing AMPK Thr172 phosphorylation (Fig. 2.1A).  Phosphorylation of AMPK at 
Thr172 mirrored the changes in phosphorylation of IKK and amount of IκBα protein, which 
served as markers of IKK activity (Fig 2.1A). 1. Compound A effectively inhibited IL-1β-
induced AMPK Thr 172 phosphorylation at 1µM (Fig. 2.6A). 
To validate the findings with Compound A, we expressed either wild type (wt) or dominant 
negative/kinase dead (kd, K44A) IKKβ in HeLa cells and then treated with IL-1β for 5 minutes.  
IL-1β induced AMPK Thr172 phosphorylation in cells expressing wtIKKβ but not in cells 
expressing kdIKKβ (Fig. 2.1B).  Knockdown of the essential IKKβ scaffold protein NEMO by 
siRNA was also sufficient to block IL-1β induced AMPK Thr 172 phosphorylation in the LKB1-
deficient A549 cells (Fig 2.1C).  This indicated that the canonical IKK complex (which is 
defined by the presence of NEMO) was required for IL-1β induced AMPK Thr 172 
phosphorylation.  Since the previous data were all conducted in LKB1-deficient cells, we next 
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tested whether the loss of LKB1 activity was required for IL-1β to induce IKK-dependent 
AMPK Thr172 phosphorylation.  Wild type mouse embryonic fibroblasts (wtMEFs) also showed 
an increase in AMPK Thr172 in response to IL-1β that was blocked by knockout of IKKβ (Fig. 
2.1D) or Compound A (Fig. 2.6B), indicating that LKB1 loss is not required for IL-1β to induce 
IKK-dependent AMPK Thr172 phosphorylation.  
While it has been reported that serum starvation induces AMPK Thr172 phosphorylation131, 
our data indicate that IL-1β induces AMPK Thr172 phosphorylation in the presence of full 
serum and that cells grown in full media (DMEM with 10% serum) exhibited a level of IL-1β 
induction of AMPK Thr172 phosphorylation that is similar to stimulated cell starved of all 
nutrients with Earle’s Balanced Salt Solution (EBSS) for 2 hours (Fig. 2.6C).  This indicated that 
IL-1β can induce AMPK Thr172 in LKB1-deficient cells experiencing energy stress.  
Previously, others demonstrated that IL-1β promotes AMPK Thr172 and ACC Ser79 
phosphorylation 117,118. To further validate that IL-1β could induce the phosphorylation of 
downstream AMPK targets we treated wtMEFs or AMPKα1 -/-, AMPKα2 -/-  knockout (AMPK 
-/-) MEFs 132 with IL-1β.  Treatment of wtMEFs with IL-1β but not AMPK -/- MEFs with IL-1β 
for 20 minutes increased the amount of phosphorylation of the two known AMPK substrates 
ACC S79 and ULK S555 (Fig. 2.1E).  IL-1β also induced ACC Ser79 phosphorylation in A549 
cells after a 30 min treatment, and this was blocked by Cmpd A (Fig. 2.1F).  
One important consequence of AMPK activation is the induction of autophagy 95,96.  
Previously it was shown that IKK is involved in the induction of autophagy in response to known 
autophagy inducers, including rapamycin and starvation media 15.  Moreover, IKK-mediated 
autophagy induction required AMPK, as knockdown of AMPK prevented constitutively active 
IKKβ from inducing autophagy15. Other reports have indicated that IL-1β could induce 
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autophagy in macrophage and epithelial cell lines 91,117,133.  Given that IL-1β induces AMPK 
activity in LKB1-deficient A549 cells, we determined whether IL-1β could induce IKK-
dependent autophagosome formation in these cells.  IL-1β increased the abundance of the 
autophagosome marker LC3-II (faster migrating LC3 band) within 20 minutes of treatment in 
A549 cells (Fig. 2.1G).  Pre-treatment with Cmpd A (Fig. 2.1H) or the AMPK inhibitor 
Dorsomorphin 134,135 (Fig. 2.61D) prevented LC3-II induction upon treatment with IL-1β, 
indicating that IL-1β induced autophagosome formation required IKK and AMPK activity.  The 
changes in LC3 mobility strongly correlated with ACC Ser79 phosphorylation, which served as a 
marker of AMPK activity (Fig. 2.1F).  IL-1β also increased the amount of staining by an 
acidified autophagosome specific dye (Fig. 2.1I).  The increased autophagosome staining was 
blocked by Compound A, indicating that IKK and AMPK activity are required for IL-1β to 
induce autophagosome formation.  Bafilomycin-A1, an established inhibitor of autophagosome 
acidification133, also prevented IL-1β induced staining (Fig. 2.1I).  This indicated that the 
increased signal from the dye was specific to increased autophagosome formation.  These results 
were not due to direct off-target inhibition of AMPK by Compound A, since Compound A was 
unable to inhibit recombinant AMPK kinase activity in a cell-free peptide based kinase assay 
(Fig. 2.61E and see Fig. 2.7B).  As a positive control, Compound A inhibited recombinant IKKβ 
activity in a peptide based kinase assay (Fig. 2.61E).  
The increase in phosphorylation of downstream AMPK targets and the increase in 
autophagosome formation in response to IL-1β indicate that the increased AMPK Thr172 
phosphorylation in response to IL-1β correlated with an increase in AMPK activity and 
promoted downstream signaling events. 
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TAK1 promotes IKK-mediated AMPK phosphorylation in response to cytokines, but TAK1 only 
partially regulates basal IKK-mediated AMPK regulation   
The signaling to AMPK from IL-1β and TNF-α occurs through TAK1-dependent canonical 
IL-1 and TNF receptor signaling pathways respectively, as pre-treatment with the TAK1 
inhibitor 5z-7-oxozeanol 136 prevented IL-1 or TNF induction of AMPK Thr172 phosphorylation 
to a similar extent as Compound A (Fig. 2.2A).  Since IKK was required for cytokine-induced 
AMPK Thr172 phosphorylation and IKK is generally thought to be downstream of TAK1 in 
cytokine signaling cascades, we next explored whether IKK functions downstream of TAK1 
with respect to AMPK Thr172 phosphorylation. Overexpression of TAK1 and the adaptor 
protein TAB1 in HeLa cells is known to be sufficient to induce AMPK Thr172 phosphorylation 
118.  To determine if IKK is required for AMPK Thr172 induction upon TAK1 and TAB1 
overexpression, HeLa cells were transfected with TAK1 and TAB1 for 48 hours and then treated 
with either DMSO or Compound A (5µM) for 1 hour.  Treatment with Compound A reduced 
both basal and TAK1/TAB1-induced AMPK Thr172 phosphorylation (Fig. 2.2B).   To further 
address the relationship between TAK1, IKKβ and AMPK, IKKβ was inhibited in mouse 
embryonic fibroblasts (MEFs) that lack TAK1 kinase activity (TAK1 -/-) 137. Knockdown of 
IKKβ or treatment with Compound A was sufficient to decrease AMPK Thr172 phosphorylation 
in TAK1 -/- MEFs  (Fig. 2.2C) indicating that IKKβ can regulate AMPK Thr172 
phosphorylation in the absence of TAK1.  TAK1 -/- MEFs had lower amounts of basal AMPK 
Thr172 phosphorylation than their wild type counterparts and the residual AMPK Thr172 
phosphorylation in TAK1 -/- MEFs was almost completely ablated by Compound A treatment.  
Similar to Compound A treatment, knockdown of IKKβ decreased AMPK Thr172 
phosphorylation in TAK1 -/- MEFS (Fig. 2.2D).  The data above indicate that TAK1 is upstream 
of IKK with respect to AMPK. However, in the absence of TAK1, residual IKK activity is 
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important for regulating the remaining AMPK Thr172 phosphorylation. In this regard, there are 
other potential sources of IKK activation including trans-autocatalytic phosphorylation (induced 
by forced proximity) 125 or activation by an alternative upstream IKK kinase such as NIK or 
MEKK3 10. In contrast to MEFs where a large portion of the basal AMPK Thr172 
phosphorylation was dependent on TAK1 (Fig. 2.2B), basal AMPK Thr172 phosphorylation in 
the LKB1-deficient cancer cell line A549 was independent of TAK1. Treatment of A549 cells 
with TAK1 inhibitors, NG-25 138or 5z-7-oxozeanol, completely abolished phosphorylation of 
p38 139 (a marker of TAK1 pathway activation), but had no effect on either AMPK Thr172 
phosphorylation or p65 Ser536 phosphorylation (a marker of IKK activity) (Fig. 2.2E). This 
indicated that the majority of the basal IKKβ and AMPK activity in these cells is independent of 
TAK1. To determine whether IKK regulates basal TAK1 activity, A549 cells were treated with 
Compound A and the amount of phospho-p38 were determined. Compound A treatment 
abolished phospho-p65, but had no effect on the ratio of phospho-p38 to total p38 (Fig. 2.2E). 
This indicated that TAK1 does not regulate basal AMPK or IKK activity in A549 cells, and that 
IKK does not regulate basal TAK1 activity.  
 
Canonical IKK regulates AMPK Thr172 phosphorylation in cancer cell lines   
 
The canonical IKK complex is a high molecular weight complex containing the kinases 
IKKα and IKKβ bound to the scaffold protein, NEMO. IKKα is also found as a homodimer in 
the non-canonical IKK complex 6,140. In order to determine the relative contributions of the 
canonical and non-canonical IKK complex in regulation of AMPK Thr172 phosphorylation, 
individual components of IKK were knocked down or inhibited.  Knockdown of NEMO, the 
essential scaffold protein of the canonical IKK complex 124, decreased AMPK Thr172 
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phosphorylation and downstream ACC Ser79 phosphorylation in A549 and MDA-MB-231 cells 
(Fig. 2.3A).  Two distinct siRNAs targeting NEMO also inhibited AMPK Th172 
phosphorylation in A549 cells, indicating that the effects of NEMO knockdown were not due to 
an off-target effect of the siRNA (Fig. 2.7A). Knockdown of either IKKα or IKKβ in A549 cells 
also led to a decrease in AMPK Thr172 phosphorylation (Fig. 2.3B). However, IKKβ 
knockdown decreased AMPK Thr172 phosphorylation and ACC Ser79 phosphorylation to a 
greater extent than IKKα (only knockdown of IKKβ caused a statistically significant decrease in 
AMPK Thr172 phosphorylation). These results suggest that the canonical IKK complex plays a 
more important role in regulating AMPK Thr172 phosphorylation than the non-canonical IKK 
complex in the A549 cells. IKKα-/-  and IKKβ -/- MEFs  mirrored the knockdown experiments 
in A549 cells, where IKKβ -/- MEFs displayed a greater decrease in AMPK Thr172 
phosphorylation compared to IKKα -/-  (Fig. 2.3C).  To corroborate the observations using 
genetic knockdowns or knockouts, A549 (LKB1-deficient) and MDA-MB-231 (normal) were 
treated with increasing concentrations of Compound A for 1 hour. Compound A treatment led to 
a dose-dependent decrease in AMPK Thr172 phosphorylation. Importantly, Compound A also 
dose-dependently decreased the ACC Ser79 phosphorylation in both cell lines (Fig. 2.3D).  The 
effect of Compound A on AMPK Thr172 phosphorylation was not due to off-target inhibition of 
other kinases as Compound A had no effect on AMPK Thr172 phosphorylation in IKKα -/-, 
IKKβ -/- double knockout MEFs (DKO, Fig. 2.7B.). Another IKK inhibitor, the NEMO Binding 
Domain Peptide (NBD peptide) which works via a distinct mechanism from Compound A 141, 
also decreased AMPK Thr 172 phosphorylation in A549 cells (Fig. 2.7C). In addition, an 
inactive enantiomeric mixture of Compound A, labeled Compound B, did not have any effect on 
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AMPK Thr172 phosphorylation in A549 cells (Fig. 2.7D), further supporting the specificity of 
Compound A towards AMPK Thr172 phosphorylation.  
Time course experiments demonstrated that a decrease in AMPK Thr172 phosphorylation 
could be observed as early as 15 minutes after Compound A treatment while maximal inhibition 
occurred from 30 to 60 minutes (Fig. 2.3E). The rapid kinetics of Compound A mediated 
inhibition of AMPK Thr172 phosphorylation suggested the possibility that IKK directly 
regulates this phosphorylation site.  
 
IKK regulates AMPK Thr172 phosphorylation independent of changes in the energy status of the 
cell  
 
AMPK activity is tightly regulated by changes in the ratio of ADP/ATP and AMP/ATP106,107 
108. An increase in the ratio of AMP/ATP or APD/ATP is indicative of energetic stress and is 
generally associated with an increase in AMPK activity. IKK and NF-κB are also known to 
regulate cellular metabolism in certain contexts 17,65, thus we sought to determine if IKK 
inhibition affects ADP/ATP and AMP/ATP ratios. A 30 minute treatment with Compound A 
(5µM) increased both the ratios of AMP/ATP and ADP/ATP (Fig. 2.8A), which indicates 
energetic stress and would be expected to increase AMPK Thr172 phosphorylation in cells with 
LBK1 activity. However, at this time and concentration, Compound A decreases AMPK Thr 172 
phosphorylation in A549 cells (Fig. 2.3E). In addition, Compound A decreased Thr172 
phosphorylation on an AMPK kinase domain mutant that cannot bind to AMP 142 (Fig. 2.8B). 
These data indicate that the effects of Compound A on AMPK activity are independent of 
changes in ADP/ATP or AMP/ATP ratios.  
IKK phosphorylates AMPK Thr172 in cell free kinase assays and induces its activity 
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To determine whether IKK regulates AMPK via direct phosphorylation, inactive 
recombinant AMPK trimers, that contain AMPKα1, AMPKβ1 and AMPKγ1 143 (purified from 
bacterial cells), were incubated with GST-IKKβ (1-786) (purified from Sf9 insect cells), in the 
presence of 32P-γ-ATP. AMPKα1 incorporated 32P when incubated with IKKβ (Fig. 2.9A). To 
map the IKK dependent phosphorylation sites on AMPK, a parallel reaction was performed with 
cold ATP and subjected to mass spectrometry. Among the phosphopeptides identified was a 
peptide that corresponded to phosphorylated Thr172 (Fig. 2.9A). Mutation of Thr172 to strongly 
reduced incorporation of 32P into AMPKα1 in the presence of active IKKβ (Fig. 2.9B). These 
findings were confirmed by western blot, where increasing amounts of IKKβ led to increased 
Thr172 phosphorylation on AMPK trimers (Fig. 2.4A).  
Since phosphorylation of AMPK at Thr172 is sufficient to increase the kinase activity of 
AMPK, we predicted that IKKβ would increase AMPK activity.  AMPK activity, as measured 
by the SAMS peptide kinase assay (see Materials and Methods), was indeed strongly increased 
after incubation with IKKβ (Fig. 2.4B).  IKK also efficiently phosphorylated a kinase-dead 
mutant of AMPK (Fig. 2.4C) indicating that the IKKβ effect on AMPK Thr172 is independent of 
AMPK autocatalytic activity. To determine if IKKα and IKKβ have differential efficacy relative 
to AMPK Thr172 phosphorylation, cell-free kinase assays were performed with either IKKα or 
IKKβ.  IKKβ phosphorylated approximately 5-fold more AMPK Thr172 than IKKα (Fig. 2.4D). 
Moreover, IKKβ is able to bind more effectively to the AMPK kinase domain than did IKKα, as 
evidenced by co-precipitation experiments in which a GST-tagged AMPK kinase domain was 
precipitated from HEK293T cells (Fig. 2.4E). This suggested that IKKβ is the dominant AMPK 
Thr172 kinase within the canonical IKK complex.  Compound A effectively inhibited IKKβ-
mediated AMPK Thr172 phosphorylation, but did not inhibit either TAK1 or CAMKK2 (two 
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other known upstream AMPK kinases) from phosphorylating AMPK Thr172 (Fig. 2.4F).  Thus 
the effect of Compound A on AMPK Thr172 phosphorylation in cells is independent of 
inhibition of either TAK1 or CAMKK2.  
 
IKK inhibition leads to a reduction in AMPK Thr172 phosphorylation in phenformin-treated 
LKB1-deficient cells and promotes apoptosis 
Phenformin is an inhibitor of complex I of the mitochondria 144-146 and leads to a depletion of 
ATP 128. To counteract the action of phenformin, AMPK is activated to conserve ATP 129.  
Phenformin- induced AMPK activity is largely dependent on the upstream AMPK activating 
kinase LKB1, and LKB1-deficient cancer cell lines are particularly sensitive to phenformin 
induced apoptosis (as measured by Caspase 3/7 activation) 128,129.  Since IKK regulates AMPK in 
LKB1-deficient cells and since IKK-mediated AMPK regulation is independent of energy status 
(Fig. 2.6C), we asked whether IKK inhibition would further sensitize these cells to phenformin-
induced apoptosis. To inhibit IKK, A549 (LKB1-deficient) and MDA-MB-231 cells (LKB1-
positive) were transfected with siRNA targeting NEMO. These cells were then treated with 
phenformin for 18 hours (Fig. 2.5A). Both A549 cells and MDA-MB-231 cells had lower basal 
AMPK Thr172 phosphorylation when NEMO was knocked down (Fig 2.3A and Fig 2.5A). 
Phenformin treatment induces AMPK Thr172 phosphorylation only in MDA-MB-231 cells and 
this effect did not change when NEMO was knocked down (Fig. 2.5A).  Accordingly, NEMO 
knockdown led to phenformin-induced apoptosis as measured by Caspase 3/7 activity in A549 
cells.  On the other hand, NEMO knockdown had no effect on Caspase 3/7 induction by 
phenformin in MDA-MB-231 cells (Fig. 2.5B). These results were corroborated with Compound 
A, where lower levels of AMPK Thr172 phosphorylation are observed upon Compound A 
treatment in combination with phenformin in A549 cells and Compound A does not effect 
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AMPK Thr172 phosphorylation in response to phenformin in MDA-MB-231 (Fig. 2.5C). This is 
consistent with previous work indicating that LKB1 is required for phenformin to induce AMPK 
Thr172 phosphorylation. This data also suggested that IKK is not required for phenformin 
induced AMPK activation, consistent with our previous findings that IKK regulates AMPK 
independent of cellular metabolic changes.  
We next tested the effects of Compound A, phenformin or the combination of the two in a 
panel of LKB1-deficient (HeLa, A549, NCI-H23, and NCI-H460) or LKB1 wt cell lines 
(IMR90, NCI-H441, MDA-MB-231 and MiaPaca-2). 1mM phenformin was used as this 
concentration since it is sufficient to induce AMPK Thr172 in LKB1 expressing cells, but does 
not induce measureable amounts of apoptosis in LKB1-deficient cells 18 hours after treatment as 
measured by Caspase 3/7 activity. On average the combination of phenformin and Compound A 
induced more Caspase 3/7 activity in LKB1-deficient cells than in LKB1-expressing cells (Fig. 
2.5D). Taken together these results indicate that IKK inhibition sensitizes LKB1-deficient cells 
to phenformin-induced apoptosis by decreasing AMPK Thr172 phosphorylation.   
 
2.4 Discussion  
Three kinases have been previously described to phosphorylate AMPK Thr172: LKB1, 
CAMKK2 and TAK1 93. While the molecular mechanisms and the biological context of LKB1 
and CAMKK2 regulation of AMPK Thr172 phosphorylation have been well described, much 
less is known about the mechanism of TAK1 regulation of AMPK Thr172. In this study, we 
show that IKK plays an important role downstream of TAK1 in regulating AMPK Thr172.  
Previous studies demonstrated that overexpression of TAK1 along with the adaptor protein 
TAB1 is sufficient to promote AMPK phosphorylation. Moreover, TAK1/TAB1 fusion proteins 
can directly phosphorylate AMPK Thr172 in cell-free kinase assays 117,118,147. It is interesting to 
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note, however, that TAK1 is not active in vitro unless the adaptor protein TAB1 is also present, 
and thus cannot phosphorylate AMPK in the absence of recombinant TAB1147. Stimuli such as 
IL-1β, TNF-α and TRAIL that activate TAK1 lead to the induction of  AMPK activity 117,118,147. 
Here we provide evidence (Fig. 2.2A) that inhibition of TAK1 prevents these stimuli from 
inducing AMPK Thr172 phosphorylation. All of this evidence led to the view that cytokine-
induced TAK1 activity leads to direct phosphorylation of AMPK Thr172 by TAK1.  
However, others published that expression of a constitutively active IKKβ mutant in HeLa 
cells (LKB1-deficient), that mimics TAK1 phosphorylation, leads to an increase in AMPK 
Thr172 phosphorylation 15. This result suggested a potential role for IKKβ downstream of TAK1 
in regulating AMPK. Here we demonstrate that IKK activates AMPK downstream of TAK1 in 
response to IL-1β or TNF-α.  
The canonical IKK complex, which is defined by the presence of NEMO 6, promoted AMPK 
activity in response to IL-1β and TNF-α (Fig. 2.1, Fig. 2.2A). In addition to the scaffold NEMO, 
the canonical IKK complex consists of two related protein kinases IKKα and IKKβ. While 
IKKα and IKKβ share homology, their activity towards different substrates in the NF-κB 
pathway varies. For example, IKKβ has higher activity towards IκBα than IKKα, but IKKα has 
a higher activity towards p100 than IKKβ 148.  With respect to AMPK, IKKβ shows a 5-fold 
preference towards Thr172 phosphorylation as compared with IKKα (Fig. 2.4D).  It is possible 
that IKKβ has more kinase activity towards AMPK Thr172 or it could be that IKKβ is directed 
to and binds AMPK more efficiently than IKKα, as was observed with GST-pull downs in 
HEK293T cells (Fig. 2.4E).  This indicated that it was IKKβ within the canonical complex that 
directly phosphorylated AMPK Thr172. However, knockdown of IKKα in A549 cells or in 
MEFs leads to a decrease in AMPK Thr172. This can be explained in a variety of ways. For 
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instance, the non-canonical IKK complex could be regulating the canonical IKK complex. 
Alternatively, IKKα could be regulating IKKβ activity within the canonical IKK complex, either 
through phosphorylation of IKKβ activation loop serines or by stabilizing the canonical 
complex. Future studies are necessary to determine whether stimuli (such as RANK ligand or 
CD40 ligand) that specifically activate the non-canonical IKKα complex promote activation of 
AMPK. Although, IKKα had less activity towards AMPK Thr172 than IKKβ, it is still possible 
that a stimulus that specifically over activates IKKα could promote AMPK activity.  
The IKK/NF-κB pathway is known to promote its own feedback in order to limit the 
response to IL-1β and TNF-α, notably by inducing the transcription of IκBα 149. Activation of 
AMPK may be another way to limit NF-κB signaling in response to these cytokines, as several 
studies have indicated that AMPK activity opposes NF-κB 150,151.  One report indicated that 
TNF-α-induced apoptosis was opposed by AMPK 152. This is in line with the role of IKK in 
promoting survival over apoptosis in response to TNF-α. Consistent with the idea that IL-1β 
induces AMPK in an IKK-dependent fashion, IL-1β promotes autophagosome formation in an 
IKK-dependent manner in A549 cells. Previous work had demonstrated that IL-1 could promote 
autophagy in breast epithelial cells 117 and in macrophages 91, which both express LKB1. Here 
we show that IL-1β induces autophagosome formation in an LKB1-deficient cell line, A549, 
indicating that IL-1β induced autophagy does not require LKB1 but instead required IKK.  In 
macrophages, Il-1β was critical for clearance of certain pathogens 91. Several studies have 
demonstrated that IKK is involved in autophagy induction, however the mechanism whereby 
IKK promotes autophagy has been poorly understood 20. It is known that IKK promotes 
transcription of autophagic genes 127, and is involved in induction of autophagosomes in response 
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to several known autophagy inducing stimuli. Importantly, knockdown of AMPK prevented the 
induction of autophagosomes by overexpression of constitutively active IKK, indicating that 
AMPK is downstream of IKK with respect to autophagy 15. Data presented here suggest a 
mechanism where IKK could be promoting autophagy by direct phosphorylation of AMPK 
Thr172.   
We also demonstrated that IKK regulates basal AMPK activity independent of TAK1, as 
inhibition of IKK in TAK1 -/- MEFs led to a decrease in AMPK Thr172 phosphorylation. In 
addition to TAK1 phosphorylation, IKKβ can also be activated by trans-auto-phosphorylation, 
which is induced by forced proximity in the presence of linear ubiquitin molecules 125, or another 
upstream signal, such as from MEKK3 or NIK 10. Regardless of the source of the residual IKK 
activity, it is clear that inhibiting IKK lowers the basal AMPK Thr172 phosphorylation in the 
absence of TAK1 activity (Fig. 2.2C-D). This is similar to what occurs in A549 cells, where 
basal IKK activity was independent of TAK1 activity.  Treatment of A549 cells with TAK1 
inhibitors had no effect on either IKK activity (as measured by phosphorylated p65) or AMPK 
activity (as measured by Thr172 phosphorylation). However, treatment of A549 cells with an 
IKK inhibitor rapidly depleted both phosphorylated AMPK and phosphorylated p65 (Fig. 2.3E).  
The loss of LKB1 in cancer promotes tumor growth, but also leaves the cells vulnerable to 
metabolic stress, such as with treatment with the mitochondrial complex I inhibitor phenformin 
128,129. Despite knowledge of this vulnerability, little progress has been made in the clinic towards 
exploiting this vulnerability. An explanation could be that LKB1-deficient cancer cells promote 
basal AMPK phosphorylation via IKK to buffer against energetic stress. In this study we 
demonstrated that IKK inhibition in LKB1-deficient cells leads to a decrease in AMPK Thr172 
phosphorylation, even when the cells are treated with phenformin (Fig. 2.5A and B). This 
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decrease in AMPK Thr172 was associated with apoptosis, as measured by Caspase 3/7 activity 
(Fig. 2.5C and D). In cells expressing LKB1, IKK had no effect on the ability of phenformin to 
induce AMPK Thr172 phosphorylation. Phenformin alone or in combination with IKK inhibition 
did not induce apoptosis cells that express LKB1.  A future therapeutic strategy might be to 
combine IKK inhibition with phenformin treatment in LKB1-deficient tumors.  
 
2.5 Materials and Methods 
Cell Culture  
All cell lines were obtained from the Lineberger Comprehensive Cancer Center Tissue 
Culture Facility and cultured in DMEM (Gibco) or RPMI (Gico), depending on ATCC 
recommendations, supplemented with 10% fetal bovine serum (Sigma), 100 U/mL penicillin, 
100 µg/mL streptomycin (Gibco), and 1 mM glutamine. Immortalized wild type mouse 
embryonic fibroblasts (MEFs) of the indicated genotypes were as described previously 127.  All 
cell lines were maintained in a humidified incubator at 37°C and 5% CO2.  
Antibodies and Compounds 
 All antibodies were purchased from Cell Signaling Technology (Danvers, Massachusetts). 
Compound A (Bayer, Bay65-1942) and Compound B were dissolved in DMSO. The TAK1 
inhibitor 5z-7-oxozeanol and the AMPK inhibitor Dorsomorphin were purchased from Tocris 
Biosciences and NG-25 was purchased from MedChem Express (Monmouth Junction, NJ). 
Phenformin Hydrochloride was purchased from Sigma Aldrich. Recombinant IL-1β was 
purchased from Peprotech (Rocky Hill, NJ) and recombinant TNF-α was purchased from 
Promega (Madison, WI). Phenformin was purchased from Cayman Chemical Company (Ann 
Arbor, MI). The NBD peptide was synthesized by American Peptide.  
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siRNA Transfections  
ON TARGETplus SMART pool siRNA or individual siRNAs (all siRNAS were pooled 
unless otherwise indicated), as well as negative control siRNA were purchased from Dharmacon 
(Thermo Scientific Pierce, Rockford, IL). Each pool was reconstituted in 1X siRNA buffer 
(Dharmacon) and diluted in DEPC-treated water to a final concentration of 20 µM. Briefly, 
1.5X105 cells were plated onto 10cm dishes and cultured as described above. The following day 
Dharmacon Transfection reagent #1 (Thermo Scientific) and 200 pmol of siRNA mixture were 
incubated for 20 minutes at room temperature and added to the cells in serum-free media. Cells 
were harvested 48-72 hours post-transfection for protein extraction preparation.  
Plasmid Transfections  
Plasmids were transfected using the XtremeGene Transfection Reagent (Roche Life Science, 
Indianapolis, IN) according to the manufacturer’s protocol. Mutations were confirmed by Sanger 
Sequencing at the UNC Genome Analysis Core. The AMPK kinase domain pEBG-AMPKα1(1-
312) (Addgene plasmid # 27632). Kinase dead AMPK 1-312 was created by mutating D157 to A 
in pEBG-AMPKα1(1-312) using a quick-change mutagenesis protocol. AMPK T172A was 
created by cloning pDONR223-AMPKα1 (Addgene plasmind # 82274) into the pDEST-27 to 
add a GST-tag using Gateway Cloning (Invitrogen). Thr172 was then mutated to alanine using a 
quick-change mutagenesis protocol.  The wild type and kinase dead mutant (K44A) IKKβ, as 
well as the TAK1 and TAB1 plasmids were kind gifts from Dr. Lewis Cantley’s lab.  
Kinase Assays 
Kinase assays were performed as described previously16. For the kinase assays using 
recombinant proteins, AMPK trimers purified from E. coli were used as previously described 143 
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(a kind gift from Dr. J. Brenman, UNC Chapel Hill).  Purified GST- tagged IKKα and β from 
Sf9 insect cells were obtained from SignalChem. The kinase buffer contained 1mM beta-
glycerolphosphate, 20mM Tris pH 7.4, 12mM MgCl2 and 100µM cold ATP. γ32P-ATP was 
added where indicated. The reactions were then subjected to SDS-PAGE and either transferred to 
a nitrocellulose membrane for western blotting (see below) or were Coomassie stained for mass 
spectrometry. The mass spectrometry experiments were performed with the UNC Proteomics 
Core Facility. The band corresponding to the AMPKα1 subunit was excised from the gel and 
digested with trypsin. Phospho-peptides were enriched using titanium dioxide, then subjected to 
LC-MS using an LTQ Orbitrap Velos (Thermo Scientific) ion trap mass spectrometer.  Peptides 
were identified using Mascot Software. For the SAMS peptides assays 94, the resulting kinase 
reactions were mixed with SAMS peptide for 15 minutes then spotted on squares of p81 
phosphocellulose paper. Each square was washed three times in 1% phosphoric acid, then dried 
and the remaining radioactivity was measured using a scintillation counter. To determine the 
effect of Compound A on AMPKα1 or IKKβ activity, peptide based kinase assays were 
performed as described previously, using 100µM ATP and 5µM Compound A  153. Active 
AMPKα1/AMPKβ1/AMPKγ1, the SAMS peptide and the IκBα peptide were obtained from 
MRC PPU Reagents and Services facility (MRC PPU, College of Life Sciences, University of 
Dundee, Scotland, mrcppureagents.dundee.ac.uk).   
Western Blotting  
Whole-cell protein extraction was performed by scraping the cells in cold 1% NP-40 buffer 
(20mM Tris pH 7.6, 1mM EDTA, 1mM EGTA, 150mM NaCl, 1% Igepal). Protein 
concentrations were determined using the Bradford Assay (Bio-Rad). Protein lysates were 
resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), 
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transferred to nitrocellulose membranes (GE Healthcare Life Sciences, Pittsburg, PA), blocked 
for 1 hour in 1X TBST containing 5% nonfat milk, and incubated overnight in corresponding 
primary antibody at 4°C. Blots were then incubated with horseradish peroxidase-labeled 
secondary antibody and developed using developed using Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare Life Sciences, Pittsburg, PA), or the Biorad chemi-
doc system. Densitometry of the relevant bands was performed using ImageJ and the values were 
normalized to either total protein or Actin as indicated in the figures. The data from independent 
biological replicates was then plotted using GraphPad Prism. For statistical analysis a two-way 
ANOVA followed by a Bonferroni post test was performed to determine statistical significance.  
GST-Pull downs  
Whole cell extracts were prepared in 1% NP-40 buffer and 5% of the extract was saved for 
use as input. The rest was allowed to rotate overnight at 4°C with Glutathione conjugated beads 
(Amersham, GE Healthcare Life Sciences).  The following day, the beads were centrifuged and 
washed 3X in 1% NP-40 buffer. Proteins were eluted from the beads by boiling in Laemmeli 
buffer and then subjected to SDS-PAGE and Western Blotting.  
Measurement of ADP/ATP and AMP/ATP Ratios  
A549 cells were treated with either DMSO or Compound A (5µM) for 30 minutes. The ratio 
of ADP/ATP and AMP/ATP was then measured at the UNC Biomarker Mass Spectrometry Core 
Facility using a protocol similar to that described in Johnsen 154. Known amounts of stable 
isotopes of ATP, ADP and AMP (purchased from Millipore Sigma) were added to each sample, 
the samples were subjected to HPLC using a Surveyor HPLC system and then analyzed on a 
Thermo Fisher TSQ-Quantum Ultra triple-quadrupole mass spectrometer.  
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Autophagosome Stain  
The autophagosome specific stain was purchased from Sigma-Aldrich (catalog # MAK-138). 
Cells were seeded at a density of 1000 cells/well of a 96 well dish. The following day the cells 
were left untreated, treated with IL-1β, or treated with IL-1β in combination with Compound A 
or bafilomycin. Cells were then washed four times in the wash buffer provided with the detection 
kit, then the mean fluorescence intensity was measured using a plate reader.  
Caspase Assays  
The Caspase-Glo reagent was purchased from Promega and used according the 
manufacturer’s instructions. Cells were seeded at a density of 1000 cells per cell of a white-
walled 96 well plate. The Caspase-Glo reagent was then directly added to the wells, placed on a 
shaker at room temperature for 30 minutes then the luminescence read using a plate reader.  
Supplementary Material:  
Fig. S1. Supplemental data associated with Figure 1.  (Fig. 2.6) 
Fig. S2. Validation of Cmpd A and siRNA specificity. (Fig. 2.7) 
Fig. S3. IKK regulates AMPK independent of changes in energy status/ATP. (Fig. 2.8) 
Fig. S4. Identification of AMPK Thr 172 by mass spectrometry. (Fig. 2.9) 
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2.6 Figures for Chapter 2 
 




Figure 2.1: AMPK Thr172 phosphorylation induced by inflammatory signals requires IKK 
 
(A.) HeLa cells were pre-treated with either DMSO or 5µM Compound A (abbreviated 
CmpdA), then treated with IL-1β (15ng/ml) for the indicated time periods. Whole cell lysates 
were then subjected to western blot analysis using the indicated antibodies (n=3).  
(B.) HeLa cells were transfected with either wtIKKβ or kdIKKβ and then treated with IL-1β 
(15ng/ml) for 5 minutes. Whole cell lysates were then subjected to western blot analysis using 
the indicated antibodies (n=2).  
(C.) A549 cells were transfected with either non-coding siRNA (siNC) or siRNA targeting 
NEMO, then stimulated with IL-1β (15ng/ml) for 5 min and probed with the indicated antibodies 
(n=3).  
(D.) WT or IKKβ -/- MEFs were treated with IL-1β for 5 minutes followed by western blot 
analysis of whole cell lysates by western blotting with the indicated antibodies (n=3).  
(E.) WT or AMPK -/- MEFs were treated with IL-1β for 30 minutes and then probed with 
antibodies of known AMPK substrates (n=3, the error bars represent the standard error of the 
mean,S.E.M, *n.d = not detected).  
(F.) A549 cells were treated with IL-1β for 30 minutes and then probed with antibodies 
against the known AMPK substrate ACC phospho-Ser79.   
(G.) A549 cells were treated with 15ng/ml IL-1β for the indicated time periods and probed for 
the autophagy marker LC3. The ratio of LC3-II/LC3-I and the normalized ratio of LC3-II to 
actin are displayed in the graph below (n=3, independent biological replicates). To test if there 
was a positive time trend, we used repeated measures linear mixed-effect model. This analysis 
revealed that there was a statistically trend of increasing LC3-II (p-value = 0.027).  
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(H.) A549 cells were pre-treated with either with DMSO or 5µM Cmpd A for 15 minutes then 
with IL-1β for 20 minutes. Whole cell extracts were then prepared and analyzed by western blot 
for the indicated proteins. (n=3, the error bars represent the S.E.M, a two-way ANOVA analysis 
was used to determine which groups were statically different, * = p<0.05). 
(I.) A549 cells were pre-treated with DMSO, Compound A(5µM) or Bafilomycin A1 (10nM) 
for 15 minutes then treated with IL-1β for 2 hours. Cells were then stained with a dye that is 
selective for acidified autophagosomes. Cells were washed 3 times and then the fluorescence 
intensity was measured (n=3, error bars represent the S.E.M.).  
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Figure 2.2 IKK is downstream of TAK1 with respect to AMPK 
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Figure 2.2:  IKK is downstream of TAK1 with respect to AMPK 
 
(A.) A549 cells were pre-treated with either the IKK inhibitor Cmpd A (5µM) or the TAK1 
inhibitor 5-z-oxozeanol (5µM) for 15 minutes then stimulated with IL-1β (15ng/ml) or TNF-α 
(15/ng/ml) for 5 min (n=3).  
(B.) HeLa cells were transfected with either an empty vector plasmid or plasmids encoding 
Flag-TAK1 and Flag-TAB1. Cells were then either treated with DMSO or Cmpd A (5µM) for 30 
minutes. Whole cell lysates were then subjected to western blot analysis with the indicated 
antibodies (n=3). A two-way ANOVA analysis was used to determine if the Compound A 
treatment was different from DMSO treatment in the TAK1/TAB1 overexpressing cells vs empty 
vector. The difference between the two groups was not statistically significant (p=0.82), 
indicating that Compound A inhibited AMPK Thr172 phosphorylation driven by TAK1/TAB1. 
(C.) Wt or TAK1 -/- MEFs were treated with Cmpd A (5µM) for 1 hour, then whole cell 
lysates were analyzed by western blot for AMPK Thr172 phosphorylation and total AMPK (n=3, 
the error bars represent the S.E.M., a two-way ANOVA analysis was used to determine which 
groups were statically different, **= p<0.01, *** = p<0.001) 
(D.) TAK1 -/- MEFs were transfected with siRNA targeting murine IKKβ and blotted for the 
indicated proteins (n=3, error bars represent S.E.M, a ratio paired t-test was performed to 
determine if the control and siIKKβ groups were significantly different, *= p<0.05).  
(E.) A549 cells were treated with either of the TAK1 inhibitors 5z-7-oxozeanol or NG-25 for 
30 mins. Whole cell extracts were then analyzed by western blot with the indicated antibodies. 
(n.d. = non detected). A549 cells were treated with Compound A at the indicated concentrations 
for 30 minutes and blotted for phospho-p38 (marker of TAK1 activity) or phospho-p65 (marker 
of IKKβ activity) (n=3).  
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Figure 2.3. IKK regulates basal AMPK T172 phosphorylation in cell lines.  
(A.) A549 (LKB1-deficient) and MDA-MB-231 (normal LKB1) were transfected with siRNA 
targeting NEMO for 48 hours then whole cell extracts were analyzed by Western blot with the 
indicated antibodies(n=3, error bars represent the S.E.M, a two-way ANOVA analysis was used 
to determine which groups were statically different, **= p<.01, *p<.05).   
(B.) A549 cells were treated with siRNA targeting either IKKα or  IKKβ for 48 hours then 
whole cell extracts were analyzed by western blot (n=3, error bars represent the S.E.M, a two-way 
ANOVA analysis was used to determine which groups were statically different, * =p<0.05).   
(C.) Whole cell extracts from Wt, IKKα -/- and IKKβ  -/- mouse embryonic fibroblasts 
(MEFs) were analyzed by western blot with antibodies for either AMPK pT172 or total 
AMPK(n=3, error bars represent the S.E.M, a two-way ANOVA analysis was used to determine 
which groups were statically different, *= p<0.05).   
(D.) A549 (LKB1-deficient) and MDA-MB-231 (normal LKB1) cells were grown in full 
media (DMEM, 10% FBS) and treated with the indicated concentrations of Cmpd A for 1 hour.  
Whole cell lysates were then evaluated by western blot with the indicated antibodies (n=3, error 
bars represent the S.E.M)  
(E.) A549 and MDA-MB-231 cells were treated with Cmpd A (5µM) for the indicated time 
periods then analyzed by western blot for AMPK Thr172 phosphorylation( n=3, error bars 
represent the S.E.M).   
  
 59 
Figure 2.4 IKK directly phosphorylates AMPK T172 in cell-free kinase assays 
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Figure 2.4. IKK phosphorylates AMPK Thr172 in cell free kinase assays and induces its 
activity.  
 
(A.)  Increasing amounts of GST-IKKβ were incubated with recombinant AMPKα1/β1/γ1 
trimers in a cell free kinase assay. The reactions were then subjected to SDS-PAGE and western 
blot analysis with the indicated antibodies.  
(B.) A cell free kinase assay was performed as in (A). The SAMS peptide and 32P-ATP were 
incubated with the reactions then spotted on p81 phosphocellulose paper. The activity of AMPK 
was calculated after subtraction of the blank reaction and the IKKβ alone reaction.  
(C.) A GST-tagged kinase dead mutant of the AMPKα1 kinase domain (AMPK D157A) was 
purified from HEK293T cells and then used as a substrate for a cell-free kinase assay with active 
IKKβ.   
(D.) Recombinant IKKα and IKKβ were incubated with AMPKα1/β1/γ1 trimers as in (A.) 
The amount of AMPK pT172 phosphorylation by IKKβ is normalized to the amount of AMPK 
pT172 phosphorylation by IKKα and is displayed below the western blot.  
(E.) A GST-tagged construct of the AMPK kinase domain which is comprised of amino acids 
1-312, (the kinase domain), was transfected into 293T cells. The amount of co-precipitation with 
either IKKα or IKKβ were then measured.  
(F.) Effect of Compound A on the phosphorylation of AMPK Thr172 by recombinant IKKβ, 
TAK1/TAB1 or CAMKK2. (n=5 for each kinase, the ratio of phosphorylated to total AMPK is 
plotted in the graphs below and the error bars represent the standard error of the mean, S.E.M).  
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Figure 2.5 IKK/AMPK provide resistance to phenformin in LKB1 -/- cells  
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Figure 2. 5: IKK/AMPK provide resistance to phenformin in LKB1 -/- cells  
(A.) A549 and MDA-MB-231 cells were transfected with either non-coding siRNA (siNC) or 
siRNA targeting NEMO (siNEMO). 48 hours after transfection the cells were treated with 
phenformin (1mM) for 18 hours. Cells were then lysed for analysis by western blot (n=3) 
(B.) A549 or MDA-MB-231 cells were pre-treated with Cmpd A (5µM) or DMSO for 15 min, 
then with phenformin (1mM) for 45 minutes. Cells were then lysed for analysis by western blot 
(n=3). 
(C.) A549 and MDA-MB-231 cells were transfected with either non-coding siRNA (siNC) or 
siRNA targeting NEMO (siNEMO). 48 hours after transfection the cells were treated with 
increasing concentrations of phenformin for 18 hours then Caspase 3/7 activity was measured 
(n=3, the error bars represent the S.E.M of biological replicates).  
(D.) A panel of LKB1-deficient (A549, HeLa, NCI-H460 and NCI-H23) and LKB1 wt cell 
lines (IMR90, NCI-H441, MDA-MB-231 and MiaPaca-2)were treated with either DMSO, 
phenformin (1mM), Cmpd A (5µM) or both (Combo) for 18 hours, then the Caspase 3/7 activity 
of each cell line was measured. Each cell line was assayed in 3 independent experiments and the 
average of the three was plotted on the graph (a two-way ANOVA was performed to determine 
which groups were statically different ** p =< .01).  
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Figure 2.6 Supplemental data associated with Figure 2.1.   
 
Supplemental Figure 2.6.  
(A.) HeLa cells were pre-treated with either DMSO or Cmpd A at the indicated concentrations 
for 15 minutes then treated with IL-1β for 5 minutes. Whole cell lysates were then subjected to 
western blot analysis with the indicated antibodies (n=2). 
(B.) wtMEFs were pre-treated with either DMSO or Cmpd A for 15 minutes the treated with 
IL-1β for 5 minutes. Whole cell lysates were then subjected to western blot analysis with the 
indicated antibodies (n=2). 
(C.) A549 cells were either grown in DMEM + 10% FBS  or starved for 2 hours using Earle’s 
Balanced Salt Solution (EBSS) then were treated with IL-1β for 5 minutes and then AMPK 
Thr172 phosphorylation was analyzed by western blot. 



























(D.) A549 cells were pre-treated with either with DMSO or 5µM Dorsomorphin (n=2) for 15 
minutes, then treated with IL-1β for 20 minutes. Whole cell extracts were then prepared and 
analyzed by western blot for the indicated proteins.  
(E.) The activity of recombinant AMPK or IKKβ was measured in the presence of the 
indicated inhibitors using either the SAMS peptide or a peptide corresponding to IκBα 
respectively. The graphs represent the S.E.M of three independent experiments.  






Supplemental Figure 2.7  
(A.) A549 cells were transfected with either one of two unique siRNA’s targeting NEMO for 
48hrs. Whole cell lysates were then subjected to western blot analysis with the indicated 
antibodies (n=3). 
(B.) IKKα -/-, IKKβ -/- double knockout MEFs (DKO) were treated with 5 µM Compound A. 
Whole cell lysates were then analyzed by western blot analysis.  The ratio of pT172 to total 
AMPK was quantified using ImageJ and plotted on the graph below (n=3, the error bars 
represent S.E.M).  
(C.) A549 cells were treated with the indicated concentrations of NBD peptide, whole cell 
lysates were prepared and blotted for the indicated proteins. The ratio of pT172 to total AMPK 
was quantified using ImageJ and plotted on the graph below. The error bars represent the S.E.M 
of three independent experiments.   
(D.) A549 cells were treated with 5µM of either Compound A or an inactive enantiomeric 








Supplemental Fig 2.8. IKK regulates AMPK independent of changes in energy status/ATP.   
(A.) A549 cells were treated with Compound A (5µM) for 30 minutes and the ratio of 
ADP:ATP and AMP:ATP was measured using  LC-MS (N=3, error bars represent the S.E.M).   
(B.) A plasmid encoding a GST-tagged kinase domain of AMPKα (1-312), which cannot bind 
AMPKγ and thus its activity is not affected by the binding of either AMP or ADP,  was 
transfected into HeLa or HEK293T cells. The cells were then treated with either DMSO or Cmpd 
A (5µM) for 1 hour. GST-AMPK was then isolated using GSH-sepharose beads and western 













Figure 2.9 Identification of AMPK Thr172 phosphorylation by mass spectrometry 
 
Supplemental Fig 2.9. Identification of AMPK Thr172 phosphorylation by mass spectrometry 
(A.) Recombinant active IKKβ was incubated with recombinant inactive AMPKα1/β1/γ1 
trimers. The resulting reaction was separated by SDS-PAGE. The band corresponding to the 
alpha subunit was digested with trypsin and subjected to mass spectrometry. A peptide 



















(B.)  Recombinant IKKβ was incubated with either wt or T172A GST-AMPKα1 purified 




3 CHAPTER 3: RAPTOR SER877 IS PHOSPHORYLATED BY TBK1 AND IS 
CORRELATED WITH SUPPRESSION OF MTORC1. 
3.1 Overview  
The role of Tank Binding Kinase 1 (TBK1) in the regulation of mTORC1 activity has been 
controversial. Some reports indicate that TBK1 activity represses mTORC1 while others suggest 
that TBK1 activates mTORC1. We report here that TBK1 is required for the inhibition of 
mTORC1 in response to serum starvation. Using an unbiased proteomics approach, we found 
that TBK1 phosphorylates a vital component of the mTORC1 complex, Raptor, at Ser877 both in 
cell-free kinase assays an in cell culture. Raptor Ser877 phosphorylation was induced by the 
pathogen-associated molecules double stranded DNA and by LPS in a TBK1 dependent manner. 
In addition, we find that Herpes Simplex Virus-1 induced Raptor Ser877 phosphorylation is 
attenuated in TBK1 -/- MEFs. The increase in Raptor Ser877 phosphorylation was correlated 
with a decrease in mTORC1 signaling as measured by phospho-p70S6K. Thus Raptor Ser877 
phosphorylation may be a marker of TBK1 mediated mTORC1 repression. Future studies are 
required to determine if this phosphorylation site is required for TBK1 mediated mTORC1 
repression. Although TBK1 is well known to promote selective autophagy by phosphorylation of 
autophagy adaptors, this could represent a mechanism whereby TBK1 promotes bulk autophagy 
though mTOR inhibition.  
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3.2 Chapter 3 Introduction  
 
The TANK-binding kinase 1 (TBK1) is an IKK related kinase that is known for its role in the 
innate immune system21.  In response to pathogens and pathogen-associated molecules, TBK1is 
recruited to the Interferon Regulatory Factor 3 (IRF3) by adaptor molecules. It then 
phosphorylates IRF3 at Ser396, which promotes its DNA binding and transcription activation 
potential. Importantly, IRF3 promotes transcription of interferons which in turn promotes 
pathogen clearance21.  
In addition to its role in innate immune activation, TBK1 can regulate the mechanistic Target 
of Rapamycin (mTOR), a kinase known as a master regulator of cell growth 25,155.  When mTOR 
is active, it promotes cell growth primarily by stimulating protein synthesis and inhibiting 
autophagy. mTOR is found in two distinct complexes, mTORC1 and mTORC2. In addition to 
mTOR, mTORC1 contains regulatory proteins Raptor, MLST8, PRAS40, and DEPTOR. The 
regulatory associated protein of mTOR, Raptor, recognizes substrates by binding to TOS-motif 
containing proteins and directing them towards the active site of the mTOR kinase domain156. 
The substrates for mTORC1 include several proteins that regulate protein translation (ex: pS70 
S6K and 4EBP-1) and autophagy (ex: Ulk1). mTORC2 on the other hand primarily 
phosphorylates Akt,  PKC and SGK1 157.  
While mTORC1 signaling is most well-characterized in response to changes in growth 
factors and nutrients, it is now appreciated that many different signaling pathways, including 
TBK1 signaling, converge on mTOR. However, the mechanism and consequences of TBK1 
mediated mTOR regulation remain incompletely understood. Several publications indicate that 
TBK1 represses mTOR activity. Overexpression of wild-type but not kinase-dead TBK1 was 
sufficient to block mTORC1 activity as measured by p70S6K phosphorylation in prostate cancer 
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cells and TBK1 mediated suppression of mTOR was linked to prostate cancer dormancy85. In a 
model of chronic innate immune activation induced by knockout of the Three-prime repair 
exonuclease 1, TBK1 was also linked to suppression of mTORC1 activity 86.  TBK1 is also 
known to promote autophagy, a process that is strongly opposed by mTORC191.  
In contrast, several publications indicated that TBK1 promotes the activation of an upstream 
activator, Akt,72 and one recent report demonstrated that TBK1 increases mTORC1 activity 
through direct phosphorylation of mTOR itself76.  TBK1 could physically interact with multiple 
components of the mTOR pathway when expressed in 293T cells69. In that study, the authors 
found a wide range of sensitivity of lung cancer cell lines to TBK1 inhibitors. Interestingly, in 
cell lines that were sensitive to TBK1 inhibition, TBK1 inhibitors decreased markers of mTOR 
activity, whereas the opposite occurred in TBK1 inhibitor resistant cell lines. This indicates that 
TBK1 activity has the opposite effect on mTOR activity in different cell lines. This 
contradiction, where some studies suggest that TBK1 activates mTORC1 while and others 
suggest that TBK1 inhibits mTORC1, indicates that the role of TBK1 in mTORC1 regulation is 
likely complex and context dependent. 
To further understand the relationship between TBK1 and mTOR signaling we decided to 
test whether TBK1 phosphorylates a critical component of the mTORC1 complex, Raptor. 
Raptor is heavily regulated by phosphorylation by a diverse set of signaling cascades and 
kinases, and this allows for fine-tuning of the mTORC1 signaling. Using a proteomics approach, 
we found that TBK1 can directly phosphorylate a Raptor at Serine 877, both in cell-free kinase 
assays and in intact cells. While phosphorylation of Raptor Serine 877 has been well-
documented (see Phosphosite.org), the function of this phosphorylation site, as well as upstream 
kinases that regulate this site, remains much less characterized. One study found that NEMO-
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Like kinase (NLK) could phosphorylate Raptor Ser877, but that the primary phosphorylation site 
for NLK was the nearby Raptor Ser863158. Another study indicated that Raptor Ser877 
phosphorylation was decreased in response to the mTOR inhibitors Torin and Rapamycin 
leading to the view that mTOR itself phosphorylates Ser877 159. However, another study 
indicated that Raptor Ser877 phosphorylation was insensitive to Rapamycin or mTOR activity 
induced by insulin160. 
The Unc-51 like kinase 1 (ULK1) is a highly conserved kinase that is required for the 
initiation of autophagy. Overexpression of ULK1 was sufficient to induce Raptor Ser877 
phosphoryalation161. Recent work has also shown that ULK1 can directly activate TBK1 by 
phosphorylation of TBK1 S17212. Thus, the induction of Raptor Ser877 phosphorylation by Ulk1 
could be a direct consequence of TBK1 activation.  
Serine 877 is located within a cluster of phosphorylation sites on Raptor known as “Cluster 
2.”160 The most well-characterized phosphorylation site in this cluster is Ser863, which can 
promote mTOR activity or inhibit mTOR activity depending on the context158,160. Only one study 
has been published in which Ser877 itself was mutated and a phenotype assessed158. In that 
particular study, expression of a phosphomimetic mutant of Raptor Ser877 did not affect the 
ability of Raptor to bind the Ragulator complex proteins. However, phosphomimetic mutations 
can only approximate serine phosphorylation, as they only have half of the negative charge as a 
true phosphorylation site. It is thus still possible that phosphorylation of Raptor Ser877 disrupts 
binding with the Ragulator proteins. 
Over-expression of Rheb, a GTP-binding protein that is known to promote mTORC1, was 
sufficient to increase the amount of this phosphorylation of Raptor Ser877160. Since Raptor 
Ser877 is followed by a proline residue, several groups have hypothesized that Ser877 is 
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phosphorylated by ERK/MAP kinases. However, Raptor Ser877 phosphorylation was not 
affected by PMA or an ERK inhibitor162. Similarly, we found that Raptor Ser877 
phosphorylation was only weakly affected by PMA in cells. Nocodazole treatment increased 
Raptor Ser877 phosphorylation; however, this was also not dependent on ERK activity 163. One 
study looked at the cellular distribution of Raptor Ser877 phosphorylation and found that the 
majority of the Raptor phosphorylated at Ser877 was localized to the centrosome in mitotic cells 
164.   
In this study, we have identified Raptor Ser877 as a direct target for TBK1, both in cells and 
in cell-free kinase assays. We found that TBK1 -/- MEFs have greater levels of mTOR activity 
than their wild-type counterparts when serum starved. Importantly, this phosphorylation site was 
correlated with a decrease in mTORC1 activity. Thus TBK1 mediated phosphorylation of Raptor 
Ser877 could be a marker of TBK1 mediated mTOR repression.  However, future studies are 
necessary to determine whether Raptor Ser877 phosphorylation required for TBK1 mediated 
mTORC1 repression.  
3.3 Results  
 
TBK1 is required mTORC1 inhibition in response to serum starvation. 
A recent report indicated that TBK1 is required for full mTORC1 activation in response to 
certain stimuli after overnight serum starvation76. However, another recent report indicated that 
the kinase ULK1, whose activity is known to be induced by serum starvation, was recently 
demonstrated to activate TBK1 by phosphorylating Ser172 in the TBK1 activation loop12.  
Accordingly, we found that serum starvation potently induced TBK1 Ser172 phosphorylation 
(Fig. 3.1A). Since TBK1 activity was induced by serum starvation, we next tested whether TBK 
played a role in regulating mTOR signaling upon serum withdrawal, as mTOR is known to be 
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rapidly inhibited by serum starvation. In wtMEFs, serum starvation led to a decrease in the 
phosphorylation of the known mTOR substrate, p70-S6K, and  marker of its activity, 
phosphorylated S6 (Fig. 3.1B). In contrast TBK1 -/- MEFs failed to fully suppress the levels of 
phospho-p70S6K in response to serum starvation, indicating that TBK1 is required for repressing 
mTORC1 in response to serum starvation.   
 
TBK1 phosphorylates Raptor Ser877 in cell-free assays and in cells 
We hypothesized that TBK1 suppresses mTOR by direct phosphorylation of a component of 
the mTORC1 complex. We immuno-precipitated myc-mTOR from HEK293T cells and 
combined the resulting precipitation with recombinant TBK1 in the presence of radiolabeled 
ATP. The addition of TBK1 to the reaction did not increase the levels of 32P-γ-ATP incorporated 
into the mTOR itself( Fig. 3.2A). However, 32P-γ-ATP was incorporated into a protein with an 
apparent molecular weight of around 150 kDa. Since the mTOR used in this reaction was 
precipitated from HEK293T cells, we speculated that TBK1 phosphorylated a protein that is 
typically found in a complex with mTOR (Fig. 3.2A).   Two proteins, Raptor (149 kDa) and 
Rictor (192 kDa) were candidate proteins for that particular band as both proteins are known to 
be tightly associated with mTOR.  We immuno-precipitated tagged Raptor or Rictor from 
HEK293Ts and found that recombinant TBK1 only showed a significant amount of activity 
towards Raptor (Fig. 3.2B). 
To map the exact TBK1 dependent phosphorylation sites on Raptor we utilized mass 
spectrometry in a cell-based model and in cell-free kinase assays. To determine which sites on 
Raptor were phosphorylated in cell-free kinase assays, we performed a reaction as in Fig. 3.2B, 
except that we did not include radiolabeled ATP in the reaction. Three reactions were performed: 
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(1) HA-Raptor (2) HA-Raptor+ATP or (3) HA-Raptor +ATP and +TBK1. The peptides 
identified from the second reaction are presumed to be from another kinase that could be co-
purified with HA-Raptor, such as mTOR.  In this way, we could tell which sites were 
specifically due to TBK1 activity and not a contaminating kinase that might be co-purified with 
HA-Raptor. The peptides enriched in the third reaction were presumed to be due to TBK1 
activity. Each reaction was separated using SDS-PAGE and then stained with Coomassie. The 
band corresponding to Raptor was then excised and subjected to mass spectrometry. In total, we 
identified nine phospho-peptides that were enriched in the samples incubated with TBK1. The 
phosphorylation sites corresponded to S44, S101, S704, S877, S982, S1027, and S1171 (Table 
1).   
We next determined which of these candidate phosphorylation sites were dependent on 
TBK1 activity in intact cells. HA-Raptor was immunoprecipitated from HEK 293T cells either 
unstimulated, stimulated with a known inducer of TBK1, phorbol myristoyl acetate (PMA) 165 , 
or a combination of PMA in conjunction with the TBK1 inhibitor AZ-5E. 166.   As in the other 
approach, we excised the band that corresponded to Raptor and performed mass spectrometry. 
Only Serine 877 was identified as TBK1 dependent in cell-free kinase assays and in cells (Fig. 
3.2C and Table 1). Several other TBK1 dependent phosphorylation sites on Raptor were also 
identified in HEK293T cells, including S696 and S863. While it appears that TBK1 can regulate 
these sites in cells, it likely does so indirectly as these sites were not TBK1 dependent in cell-free 
kinase assays (Table 1).  
To validate the mass spectrometry findings, we used a commercially available antibody that 
specifically recognizes Raptor when phosphorylated at Ser877. Overexpression of wt- but not 
kinase-dead (kdTBK1, K38A), TBK1 in HEK293T cells induced Raptor Ser877 phosphorylation 
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(Fig. 3.2D). The signal from the antibody was specific to Raptor Ser877 phosphorylation as 
mutation of Ser877 to alanine completely erased the signal.  
To determine whether endogenous TBK1 could regulate endogenous Raptor Ser877 
phosphorylation, we treated of the lung cancer cell line A549 with the dual TBK1/IKKε 
inhibitor, which led to a decrease in the relative levels of Raptor Ser877 phosphorylation (Fig. 
3.2E).  In addition, we treated MEFs with an ATP-competitive TBK1 selective inhibitor, 
Compound 1, that does not inhibit IKKε167.  Compound 1  decreases the levels of Raptor S877 
phosphorylation in wild-type mouse embryonic fibroblasts (MEFs) in a dose-dependent manner 
(Fig. 3.2F), indicating that inhibition of TBK1 activity alone is sufficient to decrease the levels of 
Raptor Ser877 phosphorylation 167.  
 
TBK1 agonists LPS and dsDNA induce Raptor S877 phosphorylation in wt but not TBK1 -/-
MEFs 
We next treated either wt or TBK1 knockout MEFs  (TBK1 -/-) with two known TBK1 
agonists, double-stranded DNA or LPS for 2 hours. Both agonists stimulated the Raptor Ser877 
phosphorylation in wild-type MEFs but not in TBK1 -/- MEFs. This induction of Raptor Ser877 
phosphorylation was associated with an increase in phospho-p70S6K relative to the total levels.  
 
HSV induces TBK1 dependent Raptor Ser877 phosphorylation independent of ICP 34.5 
Since double-stranded DNA could induce TBK1 dependent phosphorylation of Raptor 
Ser877, we next wondered whether Herpes Simplex Virus 1 (HSV-1) could also induce Raptor 
Ser877 phosphorylation, as it is known to induce the cytosolic double-stranded DNA response 168 
 77 
and  STING knockout mice, which lack the capacity to sense foreign cytosolic DNA, are more 
susceptible to HSV-1 infection than their wild-type counterparts169.  
We choose to compare two strains of HSV, one in which the viral gene ICP34.5 was deleted 
(D) and one that had this gene put back (R). We decided to use this system since ICP34.5 is 
known to bind and modulate TBK1 170. This gene product can interact with TBK1171.  However, 
disruption of the binding of ICP34.5 to TBK1 does not impact the ability of TBK1 to 
phosphorylate IRF3172.  
Interestingly, HSV was able to robustly induce the phosphorylation of Raptor Ser877 
regardless of whether or not ICP 34.5 was present (Fig. 3.4A). It could be that ICP 34.5 inhibits 
TBK1 with respect to certain substrates but not towards other substrates, such as Raptor Ser877. 
HSV-1-1ICP35.5-D  induction of Raptor Ser877 phosphorylation was significantly attenuated in 
TBK1 -/- MEFs. We choose to use HSV-ΔICP 34.5 as the HSV gene product ICP 34.5 is known 
to modulate TBK1 activity173.  An interesting future direction would to perform an infection with 
an HSV1 strain that lacks ICP27 as this gene product was shown to disrupt the STING-TBK1 
complex and would not be capable of appropriately responding to cytosolic dsDNA168.  
 
3.4 Discussion  
 
TBK1 is known to both repress and to activate mTOR, depending on the context and cell 
line. While a mechanism for TBK1 mediated activation of mTOR has been described76, a 
mechanism whereby TBK1 inhibits mTOR has not. In this study, we find that TBK1 knockout 
MEFs have higher levels of mTORC1 activity as measured by the phosphorylation of the 
mTORC1 target p70-S6K during acute serum starvation. Thus studying MEFs that have been 
serum starved for short periods of time is a good model to study TBK1 mediated mTOR 
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inhibition. Other growth conditions, such as overnight serum starvation, may be better for 
studying TBK1 mediated promotion of mTOR signaling. 
Here we describe a possible mechanism whereby TBK1 inhibits mTORC1 signaling, through 
direct phosphorylation of Raptor, a critical component of the mTORC1 complex. We have found 
that TBK1 can directly phosphorylate Raptor Ser877 and this phosphorylation is associated with 
an increase in mTOR activity. However, in this study Raptor Ser877 phosphorylation is merely 
correlated with repression of mTOR and future studies are required to determine whether Raptor 
Ser877 phosphorylation is truly required for TBK1 to inhibit mTORC1.  
Others have published that TBK1 and IKKε can phosphorylate the mTOR kinase directly to 
promote its activity 174. This work used recombinant GST-mTOR that was immobilized, and a 
panel of kinases was screened against the mTOR in vitro. The ratio of Raptor to mTOR was 
likely very different in those reactions as compared to our studies, and it is possible that the 
reactions in our study contained higher levels of Raptor (see Fig 3.2B).  The increased levels of 
Raptor in our reactions may explain why we did not find that recombinant TBK1 displayed much 
activity towards mTOR precipitated from HEK293T cells, as it may have served as a competitive 
substrate for mTOR.  
In the study mentioned above, TBK1 knockout MEFs have less mTOR activity than their 
wild-type counterparts76, which is the opposite of what is found in our study. This difference 
could be attributed to either a different genetic background of the MEFs or different growth 
conditions. We serum-starved the MEFs for short time periods before our experiments, whereas 
Bodur et al starved the cells overnight.  These differences in growth conditions could explain 
why we observed that TBK1 inhibits mTORC1 whereas others have observed that it inhibits 
mTORC1.  
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Overnight serum starvation can induce many changes in a cells grown in culture. For 
instance, serum starvation is known to induce degradation of the components of the Hippo 
pathway YAP/TAZ175 and these genes are also known to modulate TBK1/IKKε meditated 
activation of IRF3 in response to cytosolic DNA176. While these genes inhibited the ability of 
TBK1 to promote IRF3 phosphorylation, they could favor TBK1 phosphorylation of other 
substrates such as Raptor. Moreover, at least one study has indicated that YAP/TAZ can regulate 
mTOR by promoting the transcription of SLC38A1177. Another important consequence of serum 
starvation is cell-cycle arrest. Both TBK1 activity and Raptor Ser877 phosphorylation are known 
to be regulated by the cell cycle 163,178,179.  
Many studies using both targeted and unbiased proteomics have shown that Raptor is 
phosphorylated at Ser877 (see Phosphosite.org). However, the upstream kinase of this 
phosphorylation site has remained elusive. It has been reported that mTOR inhibitors reduce the 
levels of that Raptor S877, which has led to the conclusion that Raptor S877 is a direct target of 
mTOR kinase activity. Another possibility in light of the new data presented here, is that mTOR 
regulates TBK1 activity and that mTOR inhibitors decrease Raptor Ser877 phosphorylation by 
inhibition of TBK1 activity. In our hands, TBK1 knockout cells have lower levels of Raptor 
Ser877 phosphorylation than wild-type MEFs even though other markers (phospho-p70S6K) of 
mTORC1 are higher in the TBK1 -/- MEFs than wtMEFs. This means that in at least some 
instances TBK1 mediated phosphorylation of Raptor Ser877 is not directly linked to mTOR 
activity.   
The sequence around Ser877 would have led one to predict that ERK or a MAPK would be a 
likely candidate for the upstream kinase of this site, since the serine is followed by a proline. In 
contrast the consensus sequence around TBK1 phosphorylation sites (based on peptide library 
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screens) indicates that TBK1 prefers leucine or isoleucine at the +1 position. However, proline is 
also tolerated at this position for TBK1 substrates, and several bona fide TBK1 substrates have 
proline at the +1 position21. While other kinases have a very strong preference for the amino 
acids immediately surrounding the phosphorylation site, TBK1 mediated substrate recognition is 
likely to be by other means such as forced proximity.  
We should note that is is possible that TBK1 phosphorylates other serines or threonines on 
Raptor in different situations. For practical reasons, the only cell-based model we used for mass 
spectrometry for phosphorylation site mapping was HEK293T cells stimulated with PMA. It 
would be interesting to map the phosphorylation sites on Raptor from cells that have been 
stimulated with other known TBK1 agonists and determine whether the sites identified in vitro 
are also regulated by TBK1 in vivo. Several of the phosphorylation sites that we observed in cell-
free assays have never been observed before according to Phosphosite.org, meaning that these 
phosphorylation sites may be artifacts from the in vitro kinase assays conditions or may be novel 
TBK1 dependent phosphorylation sites with unknown function.  
TBK1 and IKKε are very homologous and can often phosphorylate the same substrates. An 
important future direction is to test whether IKKε also regulates Raptor Ser877.  During HSV 
infection,  Raptor Ser 877 phosphorylation is not induced until a much later time point, which 
could be consistent with a role for IKKε in regulating this site. While TBK1 is constitutively 
expressed, IKKε’s expression is induced at the level of transcription. One possibility is that 
TBK1 can react rapidly to shut off or limit mTOR by phosphorylation of Raptor Ser877 and 
IKKε promotes mTORC1 by phosphorylation of the mTOR kinase domain, as described by 
Bodur et al. at later time points. Future studies are required to determine the relative contribution 
of TBK1 and IKKε to Raptor Ser877 phosphorylation in vitro and in vivo. 
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Future studies are also necessary to determine whether Raptor Ser877 phosphorylation is 
merely correlated with inhibition of mTORC1 or if it truly plays a role in mTORC1 inhibition. 
By expressing a mutant of Raptor in which Ser877 is mutated to alanine and can therefore not be 
phosphorylated, one could determine if the phosphorylation site is required for TBK1 mediated 
mTORC1 inhibition.  Using such a mutant, one could study whether Ser877 phosphorylation is a 
key determinant in whether TBK1 promotes or inhibits mTOR signaling. This could yield 
important information about how TBK1 regulates such processes as autophagy and pathogen 
clearance,  as well as provide insight into the role of TBK1 in diseases such as cancer and 
obesity.  
  
3.5 Materials and Methods   
Cell lines, plasmids, virus strains  
All cells were maintained in DMEM (4.5g/L glucose) supplemented with 10% FBS and 
PenStrep. For serum starvation, cells were grown in serum-free media for 1 hour before the 
experiment. HeLa and HEK293T cells were from the UNC Tissue culture core facility. The wt 
and TBK -/- MEFs were as described previously166. pRK5-HA-Raptor was obtained from 
Addgene (Plasmid #8513). For immunoprecipitation experiments, HA-tag antibody-conjugated 
agarose beads were purchased from Cell Signaling Technology. The phospho Raptor Ser877 
antibody was obtained from Millipore, and all of the other antibodies were obtained from Cell 
Signaling Technology. The TBK1 inhibitor, Compound 1, was generously provided by Dr. Qing 
Zhang (UNC-Chapel Hill).  The Herpes Simplex Virus 1 strains are as described previously170.   
 
Kinase Assay 
HEK23T cells were transfected with HA-Raptor. Two days after transfection, cells were 
lysed and incubated with the HA-antibody conjugated agarose beads for 1 hour. The beads were 
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then washed three times in lysis buffer and then in kinase assay buffer. The beads were then 
incubated with the TBK1, ATP or the appropriate negative control at 30 degrees for 30 minutes. 
The reaction was stopped using Laemmli buffer.  
Mass Spectrometry (From Dr. Laura Herring)  
The mass spectrometry experiments were carried out at the UNC Proteomics Core Facility. 
Bands corresponding to Raptor were in-gel digested with trypsin overnight. Extracted peptides 
were enriched for phosphopeptides using TiO2. The TiO2 elution for each sample was analyzed 
by LC/MS/MS on an Easy nLC 1000-Qexactive HF. Samples were eluted over a 45 min gradient 
from 5-35 %B, where mobile phase A = 0.1% formic acid and mobile phase B = acetonitrile with 
0.1% formic acid. The top 15 most intense ions were chosen for HCD fragmentation. Data were 
searched against a reviewed Human UniProt database using Mascot. The parameters used were: 
10 ppm precursor ion mass tolerance, 0.02 Da product ion mass tolerance, up to two missed 
trypsin cleavage sites, carbamidomethylation of Cys was set as a fixed modification and 
oxidation of M, deamidation of N, Q, and phospho of S, T, Y were set as variable modifications. 
A peptide false discovery rate of 5% was used to filter all results.   
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3.6 Chapter 3 Figures 
 
Figure 3.1 TBK1 is required for the mTORC1 repression in response to serum starvation   
 
 
Figure 3.1 : TBK1 is required for mTORC1 repression induced by serum starvation  
(A.) Wt or TBK1 -/- MEFs were serum starved for the indicated time periods and then 
whole cell lysates were prepared and analyzed by western blot.  
(B.) As in A. The relative ratio of phosphorylated to total p70-S6K and S6 was 




Figure 3.2 Identification of Raptor Ser877 as a direct target for TBK1 phosphorylation. 
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Figure 3.2: Identification of Raptor Ser877 as a direct target for TBK1 phosphorylation. 
(A.) A kinase assay was performed with the indicated proteins as described in the materials 
and methods.  
(B.) As in A except that either HA-Raptor or Myc-Rictor were used in the kinase assay 
instead of Myc-mTOR.  
(C.) A Venn Diagram showing the phosphorylation sites identified as TBK1 dependent by 
mass spectrometry either in cell-free assays or when Raptor was precipitated directly from 
HEK293T cells. The sequence of the phospho-peptide corresponding to Raptor Ser877 is 
shown below as well as the sequence conservation of the surrounding amino acids.  
(D.) Either GST-wt or GST-kd TBK1 was overexpressed in HEK293T cells along with wither 
HA-wt-Raptor or HA-S877A-Raptor. HA-Raptor was then immuno-precipitated and 
analyzed by western blot using either the phospho-Raptor Ser877 antibody or an antibody 
that recognizes the HA-tag.  
(E.) A549 cells serum starved for 1 hour and then were treated with the AZ-5E for 1 hour. 
Whole cell lysates were prepared and analyzed by western blotting with the indicated 
antibodies.  
(F.) Wt MEFs were treated with the indicated concentrations of Compound 1 and blotted with 
the Raptor phospho Ser877 antibody.  
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Table 1.  Phosphorylation Sites Identified Using Mass Spectrometry 
 
Table 1:  
This table displays the phosphorylation sites identified using mass spectrometry as described 
in the materials and methods. The values in the table represent the normalized area of the 
peak for the isotopic cluster for the peptide. Cells highlighted in light blue were the phospho-
peptides that were called as TBK1 dependent. Cells highlighted in orange indicate 
phosphorylation sites that were not were previously identified on Phosphosite.org at the time 
of this writing.  
  
Peptide	Sequence Blank (+ATP) (+ATP	+TBK1) Blank PMA PMA+AZ-5E
44 [K].IEGSKSLAQSWR.[M] 0.3 1.2 1.5
101 [K].ALETIGANLQK.[Q] 0.0 0.0 1.0
122 [R].YKQSLDPTVDEVK.[K] 0.0 0.0 1.0
366 [R].SYNCTPVSSPR.[L] 0.6 2.0 0.4 0.8 0.0 1.2
696 704 [K].NYALPSPATTEGGSLTPVR.[D] 1.2 1.3 0.5 0.0 1.8 0.3
696 [K].NYALPSPATTEGGSLTPVR.[D] 0.3 2.5 0.3
696 [K].NYALPSPATTEGGSLTPVR.[D] 0.0 1.7 0.3
704 [K].NYALPSPATTEGGSLTPVR.[D] 0.4 1.1 1.4
711 [K].NYALPSPATTEGGSLTPVRDSPCTPR.[L] 0.7 1.6 0.7
719 [R].LRSVSSYGNIR.[A] 0.3 1.7 0.0
722 [R].SVSSYGNIR.[A] 0.3 2.1 0.6 1.5 0.0 0.5
836 [K].VLNSIAYK.[A] 0.0 0.0 1.0
854 855 [R].VLDTSSLTQSAPASPTNKGVHIHQAGGSPPASSTSSSSLTNDVAK.[Q] 0.8 1.2 0.0
857 863 [R].VLDTSSLTQSAPASPTNK.[G] 1.1 1.6 0.3
859 863 [R].VLDTSSLTQSAPASPTNK.[G] 0.0 1.0 0.0
863 [R].VLDTSSLTQSAPASPTNK.[G] 0.9 1.6 0.5 1.1 1.4 0.5
863 [R].VLDTSSLTQSAPASPTNK.[G] 1.0 1.5 0.5
863 [R].VLDTSSLTQSAPASPTNK.[G] 1.0 1.5 0.5
863 869 [R].VLDTSSLTQSAPASPTNK.[G] 0.9 1.3 0.9
877 [K].GVHIHQAGGSPPASSTSSSSLTNDVAK.[Q] 0.7 1.8 0.4 0.5 1.5 0.0
877 [K].GVHIHQAGGSPPASSTSSSSLTNDVAK.[Q] 1.1 1.2 0.6 1.4 1.4 0.2
877 884 [K].GVHIHQAGGSPPASSTSSSSLTNDVAK.[Q] 0.0 0.5 2.4
877 889 [K].GVHIHQAGGSPPASSTSSSSLTNDVAK.[Q] 0.0 0.0 1.0
Y916 [R].DLPSGRPGTTGPAGAQYTPHSHQFPR.[T] 1.0 1.8 0.1
916 [R].PGTTGPAGAQYTPHSHQFPR.[T] 0.0 1.8 0.2
937 [K].MFDKGPEQTADDADDAAGHK.[S] 0.0 1.0 0.0
937 [K].GPEQTADDADDAAGHKSFISATVQTGFCDWSAR.[Y] 1.8 0.2 0.0
982 [K].IPEEHDLESQIR.[K] 0.0 0.0 1.0
1027 [R].NPGVPSVVK.[F] 0.0 0.0 1.0
1171 [K].VQDIPTGADSCVTSLSCDSHR.[S] 0.0 0.0 1.0















Figure 3.3: LPS and dsDNA induce Raptor pS877 phosphorylation in a TBK1 dependent 
manner. 
(A.) Wt or TBK1 -/- MEFs were treated with 10ug/ml LPS and then whole cell lysates 
were prepared and analyzed by western blot for the indicated antibodies. 
(B.) As in (A.) except cells were transfected with dsDNA (2ug/ml) for 2 hours. 
 The relative intensity of the phospho-S877 to total Raptor was assessed using ImageJ. The 
normalized ratios are displayed underneath the phospho-S877 Raptor western blots.  
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Figure 3.4 HSV infection induces Raptor Ser877 phosphorylation. 
 
 
Figure 3.4.  
(A.) Wt MEFs were infected with either HSV ICP34.5 deletion (D) or revertant (R) 
strains and blotted for either phospho Ser877 or total Raptor.  
(B.) wt or TBK1 -/- MEFs were infected with HSV ΔICP34.5 for the indicated time 
periods and then analyzed by western blot analysis with the indicated antibodies.  
 89 




This chapter will discuss the ways that the work presented above adds to the body of work 
described in the introduction concerning the mechanisms by which IKK family kinases regulate 
cell growth, metabolism and autophagy. I will also present potential future scientific studies and 
ideas for therapeutic interventions that have emerged as a result of this work.  






























4.2 Section 4.2 Future Directions related to Chapter 2: “IKK phosphorylates AMPK 
Thr172”  
 
In Chapter 2 I describe the mechanism whereby canonical IKK regulates AMPK by direct 
phosphorylation of Thr172 in the kinase activation loop of the AMPK kinase domain. I 
established that IKKβ phosphorylates AMPK Thr 172 in response to the cytokines IL-1β and 
TNF-α. IKK activity was also required for the basal levels of AMPK activity in several cancer 
cell lines, and this was independent of another upstream AMPK/IKK kinase, TAK1. IKK-
mediated activation of AMPK buffered against energetic stress in cancer cells that lack the 
primary upstream AMPK activating kinase, the tumor suppressor LKB1. 
 
What is the source of basal IKK activity in cancer cells?  
Interestingly, inhibition of a known upstream IKK activating kinase TAK1 did not affect the 
basal IKK activity in specific cancer cell lines. Consequently, TAK1 inhibition did not affect the 
levels of AMPK activity observed in these same cells. While this demonstrated that IKK could 
promote AMPK Thr172 phosphorylation in the absence of TAK1 activity, it raises the question 
of how IKK is activated, if not through TAK1 dependent phosphorylation. TAK1 is well 
established to phosphorylate IKK activation loop serines in a ubiquitin-dependent manner in 
response to IL-1, TNF- and other stimuli 8. However, as demonstrated in Chapter 2, two distinct 
TAK1 inhibitors failed to inhibit IKK activity as measured by p65 Ser536 phosphorylation in the 
absence of stimulation. This observation implied to us that another source of IKK activation 
must be present in these cells.  
One potential source of IKK activation could be IKK trans-autophosphorylation. Canonical 
IKK complexes are known to autophosphorylate, especially in the presence of linear-ubiquitin 
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molecules 125. However, these linear ubiquitin chains are thought to be formed primarily upon 
stimulation, such as with IL-1. NEMO binds tightly to these linear ubiquitin chains which 
increases the local concentration of canonical IKK complexes. While these linear ubiquitin 
chains can lead IKK to autophosphorylate due to forced proximity, they also bring IKK into 
proximity with TAK1 which allows TAK1 to phosphorylate and activate IKK. It therefore 
possible that in these cells, there exists a mechanism for increasing the local IKK concentration 
without bringing IKK in proximity to TAK1.  
Another potential inducer of IKK activity is MEKK3 10. Like TAK1, MEKK3 is a member of 
the MAP3K kinase family. Knockout of MEKK3 in mouse embryonic fibroblasts blocked TNF 
from inducing IKK activity and cell-free kinase assays revealed the MEKK3 could directly 
phosphorylate IKK. However, the exact site of MEKK3 phosphorylation on IKK was not 
mapped, and it is not known whether MEKK3 has activity towards the activation loop serines of 
IKK or if it phosphorylates another site on IKK. Other work has demonstrated that 
overexpression of the adaptor protein p62 was sufficient to activate NF-κB through MEKK3 180, 
indicating that MEKK3 could activate IKK through a mechanism distinct from TAK1/TAB1 
mediated IKK activation. An inhibitor of MEKK2/3 was recently developed 181 that, importantly, 
displayed no activity against TAK1 in cell-free kinase assays. An interesting experiment would 
be to compare the effects of a TAK1 inhibitor with the MEKK2/3 inhibitor on basal IKK activity 
in cancer cells. Based on our work, one might predict that the MEKK3 inhibitor would have a 
greater effect on basal IKK activity than a TAK1 inhibitor.  
The protein p62 is known to be selectively degraded during autophagy and its degradation is 
frequently used as a marker of autophagy 182. p62 is also known to promote IKK activity and this 
is the mechanism whereby KRas drives tumorigenesis 183,184.  This mode of regulation may 
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represent a feedback mechanism whereby p62 promotes IKK activity and IKK, in turn, supports 
the autophagic degradation of p62 by increasing AMPK Thr172 phosphorylation. 
 
How does IKK recognize AMPK for phosphorylation of Thr172?  
Another interesting observation is that IKKα/β phosphorylation in the respective activation 
loop serines is hardly detectable in the absence of stimulation. However, inhibition of IKK can 
decrease the relative levels of phosphorylation of known IKK substrates even when only low 
levels of IKK phosphorylation are detectable. Phosphorylation of these kinases is well 
established to increase the activity of these kinases. This discrepancy implies that other 
mechanisms of substrate phosphorylation may occur that do not necessarily require an increase 
in IKK activity, such as forced proximity of IKK to its substrates through a specificity factor(s). 
For example, the scaffold protein NEMO, which is known to behave like a specificity factor, 
could bring IKK into proximity with AMPK and allow IKK to phosphorylate AMPK even when 
IKK activity is relatively low 20. 
AMPK Thr172 would not have been predicted to be a substrate for IKK based on previous 
information that was available about IKK substrate recognition.  In screening of peptide libraries, 
IKK appears to prefer phosphorylation of substrates with a leucine or isoleucine at the +1 
position, and has minor preferences for amino acids in other positions that surround the 
phosphorylation site target 185. However, many bona fide IKK substrates do not follow this 
phosphorylation site motif. Several early studies have also suggested that IKK could only 
phosphorylate serines and could not phosphorylate threonine residues 186. The fact that AMPK 
Thr172 does not fit the canonical IKK phosphorylation motif implies that IKK mediated AMPK 
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Thr172 phosphorylation occurs through a novel substrate recognition mechanism that has yet to 
be determined.   
 
Do other stimuli lead IKK to phosphorylate AMPK Thr172?  
I focused my studies on AMPK activity induced by IL-1β and TNF-α, as these are strong and 
well-established inducers of IKK activity, particularly of the canonical IKK complex. However, 
IKK activity is also known to be regulated by diverse other stimuli, such as DNA damage, LPS, 
and cytosolic double stranded DNA. An important future direction will be to determine whether 
IKK can lead to AMPK activation in response to pathogen exposure. 
In addition,  the tumor microenvironment often favors the activation of IKK 187. An 
important future direction will be to determine whether the milieu of cytokines present in the 
tumor microenvironment can induce IKK to phosphorylate AMPK Thr172 and what the 
consequences of this activation are for tumor growth. IL-1β and TNF-α are potent inducers of 
the canonical IKK complex, which consists of the kinases IKKα and IKKβ, in addition to the 
scaffold and specificity factor NEMO. However, another IKK complex exists which includes 
exclusively IKKα homodimers 9. This complex is activated by other stimuli, such as RANK 
ligand 9. In my studies using a cell-free kinase assay, I found that IKKβ had approximately five 
times as much activity towards AMPK Thr172 as did IKKα. This observation led me to 
conclude that, in response to stimuli of the canonical IKK complex, it was IKKβ that was 
primarily responsible for the induction of AMPK Thr172 phosphorylation. However, IKKα still 
had a measurable level of activity towards AMPK Thr172. It is, therefore, possible that other 
stimuli that promote the activity of IKKα, such as BAFF ligand,  could cause IKKα to 
phosphorylate AMPK Thr172.  
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What’s the biological significance of IKK mediated AMPK Thr172 in non-cancerous cells that 
express wild type LKB1?   
For our studies, we primarily used cells that did not express functional LKB1. It is well 
established that LBK1 is the most robust AMPK Thr172 kinase, and the decision to focus on 
LKB1 deficient cells was to prevent confounding issues and because a substantial number of 
patients harbor tumors that lack LKB1 expression. An exciting future direction would be to 
explore the role of the IKK mediated AMPK Thr172 phosphorylation in normal physiology, 
when LKB1 is expressed. I did find that IKK could regulate both basal and cytokine-induced 
AMPK Thr172 phosphorylation in cell lines that express LKB1 (MDA-MB-231, HEK293T and 
wtMEFs).  
One might expect that IKK-mediated AMPK Thr172 phosphorylation is less critical during 
energetic stress when LKB1 is present since LKB1 is such a potent inducer of AMPK Thr172 
phosphorylation. I would hypothesize that IKK-mediated AMPK regulation is more important in 
response to cytokines or in response to specific developmental cues that are known to be IKK 
dependent (for example during hematopoiesis).   
Another upstream AMPK Thr172 kinase is CAMKK2, which promotes AMPK Thr172 
phosphorylation in response to stimuli that increase the concentration of intracellular calcium 
115,116,188. Some speculate that the reason CAMKK evolved to induce AMPK Thr172 
phosphorylation is that signals that produce an increase in intracellular calcium often precede an 
increased energy demand and thus prompt the cell to alter its metabolism to compensate for  this 
increase 189. A similar situation may be the case for IKK, where cellular stimulation by a 
cytokine can often lead to substantial shifts in cellular metabolism.  
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For example, pathogen infection often leads to substantial metabolic changes. Activating 
AMPK may be a way for the cell to shut down the translation machinery preemptively so that the 
pathogen can not usurp it for its own replication. Also, AMPK activation leads to the induction 
of autophagy, which is often used by cells to degrade intracellular pathogens directly. Fighting a 
pathogen infection can be an energy-intensive process, requiring the mobilization of immune 
cells and the production of proteins and other chemicals that instantly kill the pathogen 190. For 
example, activated B-cells must produce large quantities of antibodies very rapidly in response to 
pathogens, thereby taxing cellular energy and metabolites 191. IKK-mediated AMPK Thr172 
phosphorylation may be a way to induce the metabolic shift that are necessary for the situations 
described above.  
AMPK mediates epigenetic changes by regulating EZH2 - Is there an involvement of IKK? 
A recent report indicates that AMPK phosphorylates the histone methyltransferase EZH2 to 
drive it away from the polycomb repressive complex, resulting in decreased levels of H3K27me3 
192. Another paper demonstrated that increasing the levels of H3K27me3 by inhibition of the 
demethylase prevented TNF-α induction upon LPS stimulation, indicating that H3K27me3 could 
be repressing inflammation 193. By driving AMPK Thr172 phosphorylation, IKK could also be 
driving inhibition of the EZH2-mediated increase in H3K27me3, which could make the 
promoters of certain pro-inflammatory genes more accessible to transcription factors. 
Alternatively, IKK could be driving EZH2 away from the canonical repressive complex towards 
complexes with NF-κB. EZH2 is known to either promote or inhibit NF-κB target genes in 
breast cancer, depending on the context, by binding to NF-κB transcription factors 194. Our group 
also recently published that EZH2 could positively regulate the expression of another NF-κB 
family transcription factor, RelB, in triple-negative breast cancer195. An interesting future 
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direction will be to determine whether AMPK mediates the effect of IKK on gene expression by 
modulating epigenetic changes.  
 
What is the role of AMPK in LKB1 deficient cancer cells?  
Loss of LKB1 is found in a significant number of human cancers, but loss of AMPK is 
almost never observed 196. While in the literature LKB1 loss is often considered synonymous 
with loss of AMPK activity, there is a detectable level of AMPK activity that remains in LKB1-
deficient cells. An important future direction will be to characterize the effect of this remaining 
AMPK activity on tumorigenesis. While AMPK is known to play a vital role in tumor cell 
survival during periods of energetic stress, AMPK is also known to have tumor suppressive 
capabilities 196.  
Current thinking in the fields concludes that using AMPK agonists to treat various types of 
cancer, since AMPK over-activation is known to promote growth arrest. However, this strategy 
is unlikely to work if the cells do not express functional LKB1, as most of the agonists described 
to date require LKB1 in order to promote AMPK activity. Therefore, alternative ways to activate 
AMPK in these cells will be necessary. One possible way to activate AMPK in LKB1 null cells 
may be to induce IKK mediated AMPK Thr172 phosphorylation. In Chapter 2, I demonstrated 
that treatment with the inflammatory cytokines IL-1β or TNF-α induce AMPK activity in cells 
that lack LKB1, and at least one study indicates that IL-1β can cause a cell cycle arrest in 
specific tumor cell lines 197. IKK may be required for IL-1β to induce a cell cycle arrest via 
AMPK, and IL-1β secretion by immune cells may be a mechanism for anti-tumor immunity. One 
study demonstrated that over activation of IKKβ in cancer associated fibroblasts, which leads to 
the production of cytokines that could activate IKK in cancer cells, can suppress tumor growth 
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198. Overactive IKKβ in cancer associated fibroblasts inhibit tumor growth by inducing cytokine 
activated AMPK activity and subsequent growth arrest. Therefore a strategy to inhibit LKB1 
deficient cancer growth might be to induce expression of AMPK-inducing cytokines in cancer 
associated fibroblasts. The observation that IL-1β can promote growth arrest also implies that 
one may need to use caution when inhibiting inflammatory cytokines, such as with therapeutic 
monoclonal antibodies, as their inhibition may turn off a vital growth suppressive mechanism. 
On the other hand, IKK inhibition may be a way to prevent cancer cells from appropriately 
responding to energetic stress and thus causing tumor cell death. Cytokine stimulation may be a 
signal for tumor cells that energetic stress is occurring.  The capacity of IKK to regulate AMPK 
Thr172 phosphorylation was not affected by changes in the ADP/ATP ratio, indicating that IKK 
mediated AMPK regulation was not affected by energetic stress. In addition, I demonstrated that 
IL-1 could induce AMPK Thr172 phosphorylation in LKB1 deficient cells that were starved of 
all nutrients, indicating that in theory inflammatory cytokines may be able to compensate for 
LBK1 loss in situations of energetic stress with respect to AMPK. Given that IKK mediated 
AMPK regulation is not dependent on the energy status of the cell, cytokines may be a way to 
for cells to communicate with each other about nutrient availability. This extracellular 
communication about nutrient status may be necessary for LKB1-deficient cancers. These solid 
tumors often experience energetic stress and hypoxia and therefore may need to activate AMPK 
to survive, but lack a cell intrinsic nutrient sensing mechanism to appropriately do so.  
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Figure 4.2 Exploiting the vulnerability of LKB1 deficient cells to metabolic stress in the 
clinic. 
 
In theory LKB1-deficient cancer cells have an “Achilles Heel” that should make them 
vulnerable to energetic stress, such as during mitochondrial inhibition by phenformin. In pre-
clinical studies using an animal model of lung cancer that was driven in part by the loss of 
LKB1, phenformin produced the most robust levels of apoptosis compared to other 
pharmacological agents that are known to cause metabolic stress. However, the concentrations of 
phenformin that were necessary to induce apoptosis in these models would be difficult to achieve 
in humans without producing significant harmful side-effects. The work described in Chapter 2 
indicated that inhibition of IKK could reduce the concentration of phenformin that was necessary 
to induce apoptosis in LKB1 deficient cells. In order to translate this finding into a clinical 
setting, it will be necessary to improve the way that both IKK and Complex I of the mitochondria 
are inhibited in vivo.  
As of this writing, there are no FDA approved agents that directly target IKK activity. 































199. However, the concentrations necessary to inhibit IKK would be difficult to achieve in a 
human patient.  
Most kinase inhibitors are designed to directly compete with ATP in the kinase domain, thus 
preventing the kinase from transferring a phosphate to its substrates. However, design of a 
selective ATP-competitive IKK inhibitor has been a challenge since IKK has such a high affinity 
for ATP 200. An alternative approach has been to take advantage of the fact that IKKβ binding to 
NEMO is required for many IKKβ functions. In Chapter 2, I demonstrated that the NEMO 
Binding Domain Peptide (NBD) peptide, which is known to disrupt the interaction between IKK 
and NEMO, could lead to a decrease in AMPK Thr172 phosphorylation in LKB1 deficient 
cancer cells. The challenge with this peptide for clinical use is that it shows poor solubility 
properties and does not cross the cell membranes very efficiently. An interesting future direction 
might be to design molecules that functionally mimic the NBD peptide, but have more drug-like 
properties. There are also several FDA approved drugs that target known activators of IKK such 
TNF-α and IL-1β. However, it will first be necessary to determine if inhibiting only one of these 
cytokines is sufficient to inhibit AMPK Thr172 phosphorylation in an in vivo tumor model.  
Another potential issue with IKK inhibitors could be side effects. IKKβ knockout mice are 
embryonic lethal, due to excessive liver apoptosis, and show increased sensitivity to TNF-α 201. 
In addition, several reports have indicated that in certain circumstances such as in cancer 
associated fibroblasts, IKK can have tumor suppressive functions 198. In order to avoid these 
inhibiting the tumor suppressive characteristics of CAFs, it may be necessary to target IKK 
specifically in the cancer cells rather than in the entire body.   
As far as energetic stressing agents are concerned, we chose to use phenformin as there is 
pre-clinical data using this drug in various tumor models. An early study compared several 
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energetic stress inducing agents, and found that phenformin was able to induce the most robust 
levels of apoptosis in LKB1 deficient cells129. While IKK inhibition decreased the concentration 
of phenformin that was necessary to induce apoptosis in LKB1 deficient cells, very high 
concentrations were still required to see a maximal apoptotic response. The equivalent 
concentration of phenformin in vivo is likely to be associated with very serious side effects, such 
as lactic acidosis 202. To improve upon phenformin, several novel agents. such as AG-311, have 
been described that can inhibit Complex I of the mitochondria at much lower concentrations than 
phenformin, 203. However, the safety profiles of these compounds for use in humans has still not 
been fully determined. Alternatively, one could use other compounds widely used by humans 
that can also inhibit mitochondrial Complex I. For example, the anti-helminth drug Ivermectin, 
which has been used by millions of people for decades with very minor side effects, was shown 
to inhibit mitochondrial Complex I in glioma cell lines204.   
I demonstrated that Ivermectin can indeed reduce the levels of ATP (as measured by Cell 
Titer Glo) and induce the activity of Caspase 3/7 (as measured by Caspase Glo) in two LKB1 
deficient cell lines (A549 and HeLa). These effects could be observed in the low micromolar 
range, indicating that it may be reasonable to achieve the concentrations necessary to inhibit 
Complex I of the mitochondria in patients. In contrast, two non-transformed cell lines (wtMEFs 
and IMR90) were not sensitive to Ivermectin, indicating that there may be a large therapeutic 












Figure 4.3 Effects of Ivermectin on cell viability in A549, HeLa, wtMEF and IMR90 
cells 
  
Figure 3. HeLa, A549, IMR90 or wtMEFs cells were plated in white walled 96 well plates and 
allowed to attach for 5 hours. After attachment, the cells were treated with increasing 
concentrations of Ivermectin for 14 hrs, at which point either Cell-Titer Glo or Caspase Glo 
Reagent was added to the wells and analyzed according to the manufacturer’s instructions 
(Promega). The IC50 and EC50 values were determined using Graphpad Prism software.  
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4.3 Future Directions related to Chapter3 “TBK1 phosphorylates Raptor S877 and is 
associated with repression of mTORC1”   
 
Figure 4.4 : Diagram of the cross talk between TBK1 and IKKβ with respect to mTOR and 




The TANK binding kinase 1 (TBK1) is an IKK-related kinase known for its ability to 
regulate interferon genes in response to pathogen infection. There have been contradictory 
reports with respect to TBK1 and mTORC1 signaling. Some reports indicate that TBK1 can 
inhibit mTORC1 205, while others report that TBK1 can promote mTORC1 signaling. This likely 
means that whether TBK1 promotes or inhibits mTORC1 is likely to depend on both the cell 
type and growth conditions. While a mechanism for TBK1-mediated mTORC1 promotion has 
been described 76, a mechanism for TBK1 mediated mTORC1 repression has not been described. 
In Chapter 3, we used a proteomics approach to map a TBK1 dependent phosphorylation site on 


















How does TBK1 recognize Raptor to phosphorylate it?  
One important function of Raptor is to bind to substrates containing a TOS motif and direct 
them towards mTOR for phosphorylation 156. Interestingly, TBK1 contains a TOS motif and 
deletion of this motif prevents TBK1 from inhibiting mTOR 85. This could be an interesting 
mechanism whereby a regulatory kinase recognizes Raptor for phosphorylation rather than 
Raptor recognizing a substrate for phosphorylation.    
 
What is the consequence of TBK1 mediated phosphorylation of Raptor Ser877?   
The most critical future direction is to determine the functional consequences of Raptor 
Ser877 phosphorylation. Raptor Ser877 phosphorylation was correlated with suppression of 
markers of mTORC1 activity, but this correlation does not prove causality. Future experiments 
will need to compare the levels of mTORC1 activity in cells expressing wild type and mutant 
Raptor that cannot be phosphorylated at Ser877 (i.e., Raptor serine 887 to alanine). Using this 
system, one can determine whether Ser877 phosphorylation can regulate mTORC1 complex 
formation or downstream signaling. In addition, one could determine what the effect of this 
phosphorylation event is on other outcomes. Below I will describe future experiments that 
involve assigning a function to TBK1 mediated Raptor Ser877 phosphorylation.  
 
Could TBK1 mediated inhibition of mTORC1 promote Akt activity by promoting mTORC2 
activity?  
Several reports have indicated that TBK1 and the closely related IKKε could activate Akt by 
direct phosphorylation 72,73. However, these reports are controversial in the field and may not 
reflect the full complexity of the signaling that is occurring. One possibility is that by inhibition 
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of mTORC1 complex formation or signaling, TBK1 actually favors mTORC2 activity. Greater 
levels of mTORC2 activation could explain the higher levels of Akt activity observed by others.  
 
Coordination of autophagy between canonical IKK and TBK1 downstream of IL-1  
IL-1β was found to promote autophagy in macrophages and this enhanced the clearance of 
certain pathogens that are known to be suppressed by autophagy 91. Interestingly, in that 
particular study the authors found that TBK1 was not required for the initiation of autophagy in 
response to IL-1, but was required for autophagosome maturation 91.  However, this study did not 
address the mechanism whereby TBK1 might promote autophagosome maturation, and one 
possibility is that it does so by inhibition of mTOR through Raptor Ser877. My work in Chapter 
2, on the other hand, demonstrated that IKKβ was required for the initiation of autophagy by IL-
1β. This could be an interesting mechanism whereby IKK coordinates with TBK1 to promote 
autophagy. IKKβ induces autophagy rapidly in response to IL-1β and TBK1 is required for 
autophagosome maturation at later time points after IL-1β stimulation. TBK1 is known to play 
an essential role in the selective autophagy-mediated degradation of certain types of bacteria as 
well as mitochondria 206,207. Future studies are required to determine if Raptor Ser877 
phosphorylation is required for cells to clear pathogens or dysfunctional mitochondria by 
autophagy.  
 
 Is TBK1 required for autophagy in KRas driven cancers?  
TBK1 was identified in an early shRNA screen for synthetic lethality with mutant KRas 208. 
It is possible that TBK1 is required for certain KRas driven cancers by promoting autophagy 
through limiting mTORC1 signaling. It has now become apparent that autophagy plays an 
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important role in certain types of cancer 209. TBK1 could inhibit mTORC1 in these cells by 
phosphorylation of Raptor Ser877, which would in turn stimulate autophagy.   
The role of autophagy in KRas driven cancer is likely to be context dependent, where the role 
of autophagy might be dependent on p53 mutation status. An important future direction will be 
to explore whether KRas mutant cancers that rely on autophagy have high levels of Raptor 
Ser877 phosphorylation and whether this is associated with sensitivity to autophagy inhibitors, 
such as chloroquine. This could be used as a biomarker to determine whether a patient presenting 
with a KRas mutant tumor should be treated with autophagy inhibitors.  
At the same time, others have demonstrated that whether a cell line is sensitive to TBK1 
inhibition is highly context dependent, and in some cases can be associated with the epithelial to 
mesenchymal transition 69. If TBK1 inhibitors are ever to be used clinically, it will be important 
to have a marker of which patients will respond to the inhibitor. As described for autophagy 
inhibitors, Raptor Ser877 phosphorylation could be a marker of sensitivity to TBK1 inhibitors.   
 
4.4 Concluding Remarks 
 
The IκB kinase (IKK) was initially described as the kinase responsible for phosphorylating 
IκBα, which leads to its proteasome-mediated degradation and promotion of NF-κB dependent 
transcription 1,186. 4,5.  The canonical IKK complex consists of IKKα and IKKβ. Besides the 
canonical IKKs, there are two other IKK related kinases, TBK1 and IKKε, that are key 
regulators of interferon production. While the role of the canonical IKK complex and the IKK 
related kinases in controlling NF-κB and interferon signaling is well established, many other 
roles for this kinase family have recently emerged 126. It has now become apparent that IKK and 
the IKK related kinases are essential regulators of cell growth, metabolism, and autophagy. As 
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described in Chapter 1, the IKK family of kinases regulates these processes by directly 
phosphorylating a variety of the proteins involved. In this dissertation, I have characterized two 
additional substrates for IKKβ and TBK1 respectively, both of which are well known to be 
involved in cell growth and autophagy. In Chapter 2, I demonstrated that IKKβ phosphorylates 
AMPK at Thr172 to promote its activity and that this can buffer against phenformin induced 
energetic stress. In Chapter 3, I demonstrated that the IKK related kinase TBK1 phosphorylates a 
critical component of the mTORC1 complex, Raptor, at Ser877. This phosphorylation event was 
associated with repression of mTORC1.  The work presented here lays the foundations for future 
studies concerning the interplay between inflammation and growth signaling, and for 
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